[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"BioPro, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":182},{"warningLetters":4,"total":181},[5,30,51,67,78,99,120,139,158],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},3216,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-09T04:00:00Z\">07\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiopolygen-corp-613137-07092021\">Biopolygen Corp.\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brian Nguyen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Biopolygen Corp.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2207 East Carson St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carson\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90810\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:customerservice@biopolygen.com\"> customerservice@biopolygen.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: July 9, 2021\u003Cbr>\n\u003Cbr>\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.biopolygen.com on January 7, 2021, February 26, 2021, and June 30, 2021. The FDA has observed that your website offers the “COVIGEN AG-1 Covid-19 Self Detection Kit,” the “COVIDEX AB-1 Covid-19 Self Detection Kit,” and the “COVID-19 Antigen and Antibody Combo Set” (hereafter referred to collectively as “COVID-19 Self Detection Test Kits”) for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>[1]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The Covid-19 Self Detection Test Kits are offered for sale and distributed to consumers in the United States for self-testing without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>[2]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>[3]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>We also note that different and potentially serious public health risks are presented with specimen collection and testing in the home versus a healthcare setting. Risks may include, but are not limited to, whether a lay person has the ability to collect their specimen, run the test, and interpret the test result accurately. Your website (noted above), includes statements indicating that the COVID-19 Self Detection Test Kits may be purchased directly by consumers and are intended to be used for self-testing for COVID-19, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“ACCURACY BUT FAST, EFFICIENT; ANYTIME, ANYWHERE AT YOUR PRIVACY AND CONVENIENCE.” [https:\u002F\u002Fwww.biopolygen.com\u002Fshop\u002F-Covid-19-antigen\u002Fc-p778]\u003C\u002Fli>\n\t\u003Cli>“INSTANT AND EASY ACCESS TO SCREENING CAN BE LIFE OF[sic] DEATH. SCREENING FOR YOURSELF AND YOUR FAMILY TODAY AND REPEAT THE ROUTINE SCREENINGS TO PROTECT YOURSELF.” [https:\u002F\u002Fwww.biopolygen.com\u002Fshop\u002F-Covid-19-antigen\u002Fc-p778]\u003C\u002Fli>\n\t\u003Cli>A photograph of the “COVID-19 Antigen and Antibody Combo Set” includes the following language: “SELF-SCREENING METHOD FOR EALRY PREVENTION AND EARLY TREATMENT.” [https:\u002F\u002Fwww.biopolygen.com\u002Fshop\u002F-Covid-19-antigen-antibodycombination\u002Fc-p783]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medicaldevices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>[4]\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and\u003Cbr>\nRadiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>[1]\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>[2]\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>[3]\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>[4] \u003C\u002Fstrong>\u003C\u002Fem>Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrian Nguyen\n\nBiopolygen Corp.\n\n2207 East Carson St\n\nCarson, CA 90810\n\nUnited States\n\ncustomerservice@biopolygen.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: July 9, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.biopolygen.com on January 7, 2021, February 26, 2021, and June 30, 2021. The FDA has observed that your website offers the “COVIGEN AG-1 Covid-19 Self Detection Kit,” the “COVIDEX AB-1 Covid-19 Self Detection Kit,” and the “COVID-19 Antigen and Antibody Combo Set” (hereafter referred to collectively as “COVID-19 Self Detection Test Kits”) for sale in the United States. Based on our review, these products are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19[1] in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe Covid-19 Self Detection Test Kits are offered for sale and distributed to consumers in the United States for self-testing without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[2] In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.[3] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you offer for sale products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nWe also note that different and potentially serious public health risks are presented with specimen collection and testing in the home versus a healthcare setting. Risks may include, but are not limited to, whether a lay person has the ability to collect their specimen, run the test, and interpret the test result accurately. Your website (noted above), includes statements indicating that the COVID-19 Self Detection Test Kits may be purchased directly by consumers and are intended to be used for self-testing for COVID-19, including:\n\n“ACCURACY BUT FAST, EFFICIENT; ANYTIME, ANYWHERE AT YOUR PRIVACY AND CONVENIENCE.” [https:\u002F\u002Fwww.biopolygen.com\u002Fshop\u002F-Covid-19-antigen\u002Fc-p778]\n\n“INSTANT AND EASY ACCESS TO SCREENING CAN BE LIFE OF[sic] DEATH. SCREENING FOR YOURSELF AND YOUR FAMILY TODAY AND REPEAT THE ROUTINE SCREENINGS TO PROTECT YOURSELF.” [https:\u002F\u002Fwww.biopolygen.com\u002Fshop\u002F-Covid-19-antigen\u002Fc-p778]\n\nA photograph of the “COVID-19 Antigen and Antibody Combo Set” includes the following language: “SELF-SCREENING METHOD FOR EALRY PREVENTION AND EARLY TREATMENT.” [https:\u002F\u002Fwww.biopolygen.com\u002Fshop\u002F-Covid-19-antigen-antibodycombination\u002Fc-p783]\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medicaldevices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”[4] provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and\n\nRadiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n__________________________\n\n[1] As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n[3] Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n[4] Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Biopolygen Corp.","biopolygen-corp-613137-07092021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiopolygen-corp-613137-07092021","2026-10-26T08:08:05.317522+00:00","Warning Letter","Issued","2021-08-10","613137","Medical Devices","Brian Nguyen","2026-08-20T02:42:36.245+00:00","2021-07-09",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":19,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},615,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiopreventative-company-llc-dba-biopreventative-715505-09092025\">Biopreventative Company LLC dba Biopreventative\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Biopreventative Company LLC dba Biopreventative\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14508 Lincoln Blvd 121, #120\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33176\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Support@biopreventative.com\"> Support@biopreventative.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Biopreventative:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fbiopreventative.com in August 2025 and has observed that your website offers various compounded drug products, including tadalafil.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claim concerning your compounded tadalafil products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claim concerning your compounded tadalafil products appears on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Tadalafil (commonly known as Cialis) is a compound medication.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claim identified in this letter puts you on notice of our concerns but does not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded tadalafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The tadalafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nBiopreventative Company LLC dba Biopreventative\n\n14508 Lincoln Blvd 121, #120\n\nMiami, FL 33176\n\nUnited States\n\nSupport@biopreventative.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nBiopreventative:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fbiopreventative.com in August 2025 and has observed that your website offers various compounded drug products, including tadalafil.1 As described below, your claim concerning your compounded tadalafil products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claim concerning your compounded tadalafil products appears on your website:\n“Tadalafil (commonly known as Cialis) is a compound medication.”\nCompounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claim identified in this letter puts you on notice of our concerns but does not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded tadalafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_________________________\n1 The tadalafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Biopreventative Company LLC dba Biopreventative","biopreventative-company-llc-dba-biopreventative-715505-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbiopreventative-company-llc-dba-biopreventative-715505-09092025","2026-10-26T08:08:05.359086+00:00","2025-09-16","715505","Drugs","2026-08-19T16:19:26.368+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-09",{"id":52,"raw":53,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":42,"fei_number":19,"letter_url":62,"updated_at":63,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":64,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":65,"body_fetched_at":66,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},611,[54,34,55,36,56,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faytu-biopharma-716599-09092025\">Aytu Biopharma\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Josh Disbrow\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aytu Biopharma\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7900 E. Union Avenue, Suite 920\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denver\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80237\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Dear Josh Disbrow:\u003C\u002Fp>\u003Cp>As part of its monitoring and surveillance program, the U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, Aytu Biopharma’s (Aytu) sponsored links\u003Ca id=\"footnoteref1_aw4wp8e\" href=\"#footnote1_aw4wp8e\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;for ADZENYS XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII (Adzenys XR-ODT). FDA has determined that the sponsored links are false or misleading. Thus, the sponsored links misbrand Adzenys XR-ODT and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5); 314.81(b)(3)(i). These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression about the safety and efficacy of Adzenys XR-ODT, a Schedule II controlled substance that bears a boxed warning due to the high potential for abuse and misuse, which can lead to overdose, death, and the development of a substance use disorder, including addiction.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Adzenys XR-ODT.\u003Ca id=\"footnoteref2_lb5gj5o\" href=\"#footnote2_lb5gj5o\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>&nbsp;According to the INDICATIONS AND USAGE section of the FDA-approved Prescribing Information (PI):\u003C\u002Fp>\u003Cp>ADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.\u003C\u002Fp>\u003Cp>The PI for Adzenys XR-ODT contains a boxed warning regarding a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Adzenys XR-ODT is contraindicated in patients with a known hypersensitivity to amphetamine or other components of Adzenys XR-ODT and in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs. In addition, the PI for Adzenys XR-ODT includes warnings and precautions regarding risks to patients with serious cardiac disease; increased blood pressure and heart rate; psychiatric adverse reactions; long-term suppression of growth in pediatric patients; peripheral vasculopathy, including Raynaud’s phenomenon; serotonin syndrome; motor and verbal tics, and worsening of Tourette’s syndrome; and potential for overdose due to medication errors. The most common adverse reactions associated with single-entity amphetamine product extended-release capsules are loss of appetite, abdominal pain, insomnia, emotional lability, vomiting, nervousness, fever, nausea, infection, weight loss, accidental injury, asthenia, dyspepsia, dizziness, headache, dry mouth, diarrhea, agitation, anxiety, tachycardia, and urinary tract infection.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\u003Cp>The sponsored links are misleading because they include representations about the efficacy of Adzenys XR-ODT but fail to communicate \u003Cstrong>any\u003C\u002Fstrong> risk information. For example, the sponsored links for Adzenys XR-ODT appearing in searches include the statement “Adzenys XR-ODT for ADHD.”\u003C\u002Fp>\u003Cp>We acknowledge that some variations of the sponsored links include the statements “Medication Guide”, “Important Safety Info”, and\u002For “Side Effects”; however, these statements, alone or in combination, do not mitigate the misleading omission of risk information. By omitting risk information associated with Adzenys XR-ODT, the sponsored links fail to provide material information about the consequences that may result from the use of the drug and create a misleading impression about the drug’s safety.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Use Required Established Name\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The established name of a prescription drug must be presented prominently, in direct conjunction with the proprietary name. The sponsored links fail to present the established name for Adzenys XR-ODT, thereby misbranding the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Submit Under Form FDA-2253\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the sponsored links was not submitted to FDA under cover of Form FDA-2253 at the time of initial publication as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, the sponsored links misbrand Adzenys XR-ODT and make the distribution of the drug in violation of the FD&amp;C Act. 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5). Furthermore, Aytu did not comply with 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Adzenys XR-ODT that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Adzenys XR-ODT.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Adzenys XR-ODT; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\u003Cp>Please direct your response to the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B AmmendaleRoad, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 303 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to CDEROPDP- RPM@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>CARTER M BEACH\u003Cbr>09\u002F09\u002F2025 05:08:14 PM\u003Cbr>On behalf of George Tidmarsh, M.D., Ph.D\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F188772\u002Fdownload?attachment\">Promotional Material\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_aw4wp8e\">\u003Ca href=\"#footnoteref1_aw4wp8e\">1\u003C\u002Fa>Available at https:\u002F\u002Fwww.google.com (last accessed September 5, 2025).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_lb5gj5o\">\u003Ca href=\"#footnoteref2_lb5gj5o\">2\u003C\u002Fa>This information is for background purposes only and does not necessarily represent the risk information that\nshould be included in the promotional communication(s) cited in this letter.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJosh Disbrow\n\nRecipient Title\n\nChief Executive Officer\n\nAytu Biopharma\n\n7900 E. Union Avenue, Suite 920\n\nDenver, CO 80237\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nDear Josh Disbrow:\nAs part of its monitoring and surveillance program, the U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, Aytu Biopharma’s (Aytu) sponsored links1 for ADZENYS XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII (Adzenys XR-ODT). FDA has determined that the sponsored links are false or misleading. Thus, the sponsored links misbrand Adzenys XR-ODT and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5); 314.81(b)(3)(i). These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression about the safety and efficacy of Adzenys XR-ODT, a Schedule II controlled substance that bears a boxed warning due to the high potential for abuse and misuse, which can lead to overdose, death, and the development of a substance use disorder, including addiction.\nBackground\nBelow are the indication and summary of the most serious and most common risks associated with the use of Adzenys XR-ODT.2 According to the INDICATIONS AND USAGE section of the FDA-approved Prescribing Information (PI):\nADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older.\nThe PI for Adzenys XR-ODT contains a boxed warning regarding a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Adzenys XR-ODT is contraindicated in patients with a known hypersensitivity to amphetamine or other components of Adzenys XR-ODT and in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs. In addition, the PI for Adzenys XR-ODT includes warnings and precautions regarding risks to patients with serious cardiac disease; increased blood pressure and heart rate; psychiatric adverse reactions; long-term suppression of growth in pediatric patients; peripheral vasculopathy, including Raynaud’s phenomenon; serotonin syndrome; motor and verbal tics, and worsening of Tourette’s syndrome; and potential for overdose due to medication errors. The most common adverse reactions associated with single-entity amphetamine product extended-release capsules are loss of appetite, abdominal pain, insomnia, emotional lability, vomiting, nervousness, fever, nausea, infection, weight loss, accidental injury, asthenia, dyspepsia, dizziness, headache, dry mouth, diarrhea, agitation, anxiety, tachycardia, and urinary tract infection.\nFalse or Misleading Risk Presentation\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\nThe sponsored links are misleading because they include representations about the efficacy of Adzenys XR-ODT but fail to communicate any risk information. For example, the sponsored links for Adzenys XR-ODT appearing in searches include the statement “Adzenys XR-ODT for ADHD.”\nWe acknowledge that some variations of the sponsored links include the statements “Medication Guide”, “Important Safety Info”, and\u002For “Side Effects”; however, these statements, alone or in combination, do not mitigate the misleading omission of risk information. By omitting risk information associated with Adzenys XR-ODT, the sponsored links fail to provide material information about the consequences that may result from the use of the drug and create a misleading impression about the drug’s safety.\nFailure to Use Required Established Name\nThe established name of a prescription drug must be presented prominently, in direct conjunction with the proprietary name. The sponsored links fail to present the established name for Adzenys XR-ODT, thereby misbranding the product.\nFailure to Submit Under Form FDA-2253\nFDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the sponsored links was not submitted to FDA under cover of Form FDA-2253 at the time of initial publication as required by 21 CFR 314.81(b)(3)(i).\nConclusion and Requested Action\nFor the reasons discussed above, the sponsored links misbrand Adzenys XR-ODT and make the distribution of the drug in violation of the FD&C Act. 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5). Furthermore, Aytu did not comply with 21 CFR 314.81(b)(3)(i).\nThis letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Adzenys XR-ODT that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Adzenys XR-ODT.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Adzenys XR-ODT; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\nPlease direct your response to the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B AmmendaleRoad, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 303 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to CDEROPDP- RPM@fda.hhs.gov.\n\nSincerely,\n{See appended electronic signature page}\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nCARTER M BEACH\n09\u002F09\u002F2025 05:08:14 PM\nOn behalf of George Tidmarsh, M.D., Ph.D\n\nPromotional Material\n\n1Available at https:\u002F\u002Fwww.google.com (last accessed September 5, 2025).\n\n2This information is for background purposes only and does not necessarily represent the risk information that\nshould be included in the promotional communication(s) cited in this letter.","Aytu Biopharma","aytu-biopharma-716599-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faytu-biopharma-716599-09092025","2026-10-26T08:07:59.721246+00:00","716599","Josh Disbrow","2026-08-19T16:19:04.969+00:00",{"id":68,"raw":69,"subject":57,"body_html":71,"body_text":72,"firm_name":60,"letter_id":73,"created_at":42,"fei_number":19,"letter_url":74,"updated_at":75,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":76,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":65,"body_fetched_at":77,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},610,[54,34,70,36,56,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faytu-biopharma-716604-09092025\">Aytu Biopharma\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Josh Disbrow\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aytu Biopharma\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7900 E. Union Avenue, Suite 920\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denver\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80237\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Dear Josh Disbrow:\u003C\u002Fp>\u003Cp>As part of its monitoring and surveillance program, the U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, Aytu Biopharma’s (Aytu) sponsored links\u003Ca id=\"footnoteref1_2dmuu77\" href=\"#footnote1_2dmuu77\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;for COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating tablets), CII (Cotempla XR-ODT). FDA has determined that the sponsored links are false or misleading. Thus, the sponsored links misbrand Cotempla XR-ODT and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5); 314.81(b)(3)(i). These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression about the safety and efficacy of Cotempla XR-ODT, a Schedule II controlled substance that bears a boxed warning due to the high potential for abuse and misuse, which can lead to overdose, death, and the development of a substance use disorder, including addiction.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Cotempla XR-ODT.\u003Ca id=\"footnoteref2_zq9us4e\" href=\"#footnote2_zq9us4e\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>&nbsp;According to the INDICATIONS AND USAGE section of the PI:\u003C\u002Fp>\u003Cp>COTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.\u003C\u002Fp>\u003Cp>The PI for Cotempla XR-ODT contains a boxed warning regarding a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Cotempla XR-ODT is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Cotempla XR-ODT and in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI. In addition, the PI for Cotempla XR-ODT includes warnings and precautions regarding risks to patients with serious cardiac disease; increased blood pressure and heart rate; psychiatric adverse reactions; priapism; peripheral vasculopathy, including Raynaud’s phenomenon; long-term suppression of growth in pediatric patients; acute angle closure glaucoma; increased intraocular pressure and glaucoma; and motor and verbal tics, and worsening of Tourette’s syndrome. The most common adverse reactions associated with methylphenidate products like Cotempla XR-ODT are appetite decreased, weight decreased, nausea, abdominal pain, dyspepsia, dry mouth, vomiting, insomnia, anxiety, nervousness, restlessness, affect lability, agitation, irritability, dizziness, vertigo, tremor, blurred vision, blood pressure increased, heart rate increased, tachycardia, palpitations, hyperhidrosis, and pyrexia.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\u003Cp>The sponsored links are misleading because they include representations about the efficacy of Cotempla XR-ODT but fail to communicate \u003Cstrong>any\u003C\u002Fstrong> risk information. For example, the sponsored links for Cotempla XR-ODT appearing in searches include statements such as “Cotempla XR-ODT for ADHD” or “Cotempla XR-ODT Works Fast - Once-Daily ADHD Medication” in the headline.\u003C\u002Fp>\u003Cp>We acknowledge that some variations of the sponsored links include the statements “Medication Guide”, “Important Safety Info”, and\u002For “Side Effects”; however, these statements, alone or in combination, do not mitigate the misleading omission of risk information. By omitting risk information associated with Cotempla XR-ODT, the sponsored links fail to provide material information about the consequences that may result from the use of the drug and create a misleading impression about the drug’s safety.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims about Efficacy\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Promotional communications misbrand a drug if they are false or misleading with respect to efficacy. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\u003Cp>The sponsored links for Cotempla XR-ODT include misleading representations about its efficacy, such as:\u003C\u002Fp>\u003Cp>\u003Cstrong>Cotempla XR-ODT for ADHD – Concerta Substitute\u003C\u002Fstrong> Learn how Cotempla XR-ODT may help your child. Talk to your child’s doctor today. Having a hard time finding Concerta? Equivalent option to Concerta is available. Medication Guide. Important Safety Info. Patient Savings Offer.\u003C\u002Fp>\u003Cp>The representation that Cotempla XR-ODT is a “substitute” for or is “equivalent” to Concerta® is misleading because it suggests that Cotempla XR-ODT is therapeutically equivalent to, and therefore substitutable for, Concerta, when that has not been demonstrated. Cotempla XR-ODT and Concerta are variations of methylphenidate;\u003Ca id=\"footnoteref3_ye8gdp2\" href=\"#footnote3_ye8gdp2\">\u003Csup>3\u003C\u002Fsup>\u003C\u002Fa>&nbsp;however, they have not been shown to be therapeutically equivalent to one another.\u003Ca id=\"footnoteref4_h5bob3w\" href=\"#footnote4_h5bob3w\">\u003Csup>4\u003C\u002Fsup>\u003C\u002Fa>&nbsp;An approved drug may be determined to be therapeutically equivalent to another if it is a pharmaceutical equivalent for which bioequivalence has been demonstrated, and it can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.\u003Ca id=\"footnoteref5_ga1f2zc\" href=\"#footnote5_ga1f2zc\">\u003Csup>5\u003C\u002Fsup>\u003C\u002Fa>&nbsp;In this case, the Cotempla XR-ODT PI states a dosage form, dosage strength, and maximum daily dosage that are different from those of Concerta. For example, the PI for Cotempla XR-ODT states that the drug is an extended-release orally disintegrating tablet, with dosage strengths of 8.6 mg, 17.3 mg, and 25.9 mg, and a maximum daily dosage not to exceed 51.8 mg. On the other hand, the Concerta PI states the drug is a tablet to be swallowed whole, with dosage strengths of 18 mg, 27 mg, 36 mg, and 54 mg, and a maximum daily dosage of 54 mg in children and 72 mg in adolescents and adults. Given Cotempla XR-ODT’s differences from Concerta in dosage form, dosage strengths, and maximum daily dosage, the drugs are not substitutable and representations suggesting the drugs are “equivalent” are misleading.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Use Required Established Name\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The established name of a prescription drug must be presented prominently, in direct conjunction with the proprietary name. The sponsored links fail to present the established name for Cotempla XR-ODT, thereby misbranding the product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Submit Under Form FDA-2253\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the sponsored links was not submitted to FDA under cover of Form FDA-2253 at the time of initial publication as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, the sponsored links misbrand Cotempla XR-ODT and make the distribution of the drug in violation of the FD&amp;C Act. 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5). Furthermore, Aytu did not comply with 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Cotempla XR-ODT that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Cotempla XR-ODT.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Cotempla XR-ODT; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\u003Cp>Please direct your response to the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 143 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to CDEROPDP- RPM@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>CARTER M BEACH\u003Cbr>09\u002F09\u002F2025 05:08:26 PM\u003Cbr>On behalf of George Tidmarsh, M.D., Ph.D\u003C\u002Fp>\u003Cp>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F188771\u002Fdownload?attachment\">Promotional Material\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_2dmuu77\">\u003Ca href=\"#footnoteref1_2dmuu77\">1\u003C\u002Fa>Available at https:\u002F\u002Fwww.google.com (last accessed September 8, 2025).\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_zq9us4e\">\u003Ca href=\"#footnoteref2_zq9us4e\">2\u003C\u002Fa>This information is for background purposes only and does not necessarily represent the risk information that\nshould be included in the promotional communication(s) cited in this letter.\u003C\u002Fli>\n                      \u003Cli id=\"footnote3_ye8gdp2\">\u003Ca href=\"#footnoteref3_ye8gdp2\">3\u003C\u002Fa>Cotempla XR-ODT was approved as a 505(b)(2) application, referencing Metadate CD (methylphenidate\nhydrochloride).\u003C\u002Fli>\n                      \u003Cli id=\"footnote4_h5bob3w\">\u003Ca href=\"#footnoteref4_h5bob3w\">4\u003C\u002Fa>Electronic Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations, current through\nMarch 2025. Available at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fob\u002Findex.cfm (last accessed September 8,\n2025)\u003C\u002Fli>\n                      \u003Cli id=\"footnote5_ga1f2zc\">\u003Ca href=\"#footnoteref5_ga1f2zc\">5\u003C\u002Fa>21 CFR 314.3(b)\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJosh Disbrow\n\nRecipient Title\n\nChief Executive Officer\n\nAytu Biopharma\n\n7900 E. Union Avenue, Suite 920\n\nDenver, CO 80237\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nDear Josh Disbrow:\nAs part of its monitoring and surveillance program, the U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, Aytu Biopharma’s (Aytu) sponsored links1 for COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating tablets), CII (Cotempla XR-ODT). FDA has determined that the sponsored links are false or misleading. Thus, the sponsored links misbrand Cotempla XR-ODT and make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5); 314.81(b)(3)(i). These violations are especially concerning from a public health perspective because the promotional communications create a misleading impression about the safety and efficacy of Cotempla XR-ODT, a Schedule II controlled substance that bears a boxed warning due to the high potential for abuse and misuse, which can lead to overdose, death, and the development of a substance use disorder, including addiction.\nBackground\nBelow are the indication and summary of the most serious and most common risks associated with the use of Cotempla XR-ODT.2 According to the INDICATIONS AND USAGE section of the PI:\nCOTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.\nThe PI for Cotempla XR-ODT contains a boxed warning regarding a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Cotempla XR-ODT is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Cotempla XR-ODT and in patients receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs) or within 14 days following discontinuation of treatment with an MAOI. In addition, the PI for Cotempla XR-ODT includes warnings and precautions regarding risks to patients with serious cardiac disease; increased blood pressure and heart rate; psychiatric adverse reactions; priapism; peripheral vasculopathy, including Raynaud’s phenomenon; long-term suppression of growth in pediatric patients; acute angle closure glaucoma; increased intraocular pressure and glaucoma; and motor and verbal tics, and worsening of Tourette’s syndrome. The most common adverse reactions associated with methylphenidate products like Cotempla XR-ODT are appetite decreased, weight decreased, nausea, abdominal pain, dyspepsia, dry mouth, vomiting, insomnia, anxiety, nervousness, restlessness, affect lability, agitation, irritability, dizziness, vertigo, tremor, blurred vision, blood pressure increased, heart rate increased, tachycardia, palpitations, hyperhidrosis, and pyrexia.\nFalse or Misleading Risk Presentation\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\nThe sponsored links are misleading because they include representations about the efficacy of Cotempla XR-ODT but fail to communicate any risk information. For example, the sponsored links for Cotempla XR-ODT appearing in searches include statements such as “Cotempla XR-ODT for ADHD” or “Cotempla XR-ODT Works Fast - Once-Daily ADHD Medication” in the headline.\nWe acknowledge that some variations of the sponsored links include the statements “Medication Guide”, “Important Safety Info”, and\u002For “Side Effects”; however, these statements, alone or in combination, do not mitigate the misleading omission of risk information. By omitting risk information associated with Cotempla XR-ODT, the sponsored links fail to provide material information about the consequences that may result from the use of the drug and create a misleading impression about the drug’s safety.\nFalse or Misleading Claims about Efficacy\nPromotional communications misbrand a drug if they are false or misleading with respect to efficacy. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\nThe sponsored links for Cotempla XR-ODT include misleading representations about its efficacy, such as:\nCotempla XR-ODT for ADHD – Concerta Substitute Learn how Cotempla XR-ODT may help your child. Talk to your child’s doctor today. Having a hard time finding Concerta? Equivalent option to Concerta is available. Medication Guide. Important Safety Info. Patient Savings Offer.\nThe representation that Cotempla XR-ODT is a “substitute” for or is “equivalent” to Concerta® is misleading because it suggests that Cotempla XR-ODT is therapeutically equivalent to, and therefore substitutable for, Concerta, when that has not been demonstrated. Cotempla XR-ODT and Concerta are variations of methylphenidate;3 however, they have not been shown to be therapeutically equivalent to one another.4 An approved drug may be determined to be therapeutically equivalent to another if it is a pharmaceutical equivalent for which bioequivalence has been demonstrated, and it can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.5 In this case, the Cotempla XR-ODT PI states a dosage form, dosage strength, and maximum daily dosage that are different from those of Concerta. For example, the PI for Cotempla XR-ODT states that the drug is an extended-release orally disintegrating tablet, with dosage strengths of 8.6 mg, 17.3 mg, and 25.9 mg, and a maximum daily dosage not to exceed 51.8 mg. On the other hand, the Concerta PI states the drug is a tablet to be swallowed whole, with dosage strengths of 18 mg, 27 mg, 36 mg, and 54 mg, and a maximum daily dosage of 54 mg in children and 72 mg in adolescents and adults. Given Cotempla XR-ODT’s differences from Concerta in dosage form, dosage strengths, and maximum daily dosage, the drugs are not substitutable and representations suggesting the drugs are “equivalent” are misleading.\nFailure to Use Required Established Name\nThe established name of a prescription drug must be presented prominently, in direct conjunction with the proprietary name. The sponsored links fail to present the established name for Cotempla XR-ODT, thereby misbranding the product.\nFailure to Submit Under Form FDA-2253\nFDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the sponsored links was not submitted to FDA under cover of Form FDA-2253 at the time of initial publication as required by 21 CFR 314.81(b)(3)(i).\nConclusion and Requested Action\nFor the reasons discussed above, the sponsored links misbrand Cotempla XR-ODT and make the distribution of the drug in violation of the FD&C Act. 21 U.S.C. 352(a), (e)(1)(B), (n); 321(n); 331(a). See 21 CFR 201.10(g)(1); 202.1(b)(1); 202.1 (e)(5). Furthermore, Aytu did not comply with 21 CFR 314.81(b)(3)(i).\nThis letter notifies you of our concerns and provides you with an opportunity to address them. You should take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading as described above). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Cotempla XR-ODT that contain representations such as those described above, and explaining your plan for discontinuation of such communications, or for ceasing distribution of Cotempla XR-ODT.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. We recommend that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Cotempla XR-ODT; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\nPlease direct your response to the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 143 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to CDEROPDP- RPM@fda.hhs.gov.\n\nSincerely,\n{See appended electronic signature page}\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nCARTER M BEACH\n09\u002F09\u002F2025 05:08:26 PM\nOn behalf of George Tidmarsh, M.D., Ph.D\nPromotional Material\n\n1Available at https:\u002F\u002Fwww.google.com (last accessed September 8, 2025).\n\n2This information is for background purposes only and does not necessarily represent the risk information that\nshould be included in the promotional communication(s) cited in this letter.\n\n3Cotempla XR-ODT was approved as a 505(b)(2) application, referencing Metadate CD (methylphenidate\nhydrochloride).\n\n4Electronic Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations, current through\nMarch 2025. Available at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fob\u002Findex.cfm (last accessed September 8,\n2025)\n\n521 CFR 314.3(b)","aytu-biopharma-716604-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faytu-biopharma-716604-09092025","2026-10-26T08:07:59.762191+00:00","716604","2026-08-19T16:19:09.95+00:00",{"id":79,"raw":80,"subject":85,"body_html":86,"body_text":87,"firm_name":88,"letter_id":89,"created_at":90,"fei_number":19,"letter_url":91,"updated_at":92,"action_type":22,"case_status":23,"posted_date":93,"marcs_cms_no":94,"product_type":26,"closeout_date":19,"issuing_office":95,"recipient_name":96,"body_fetched_at":97,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":98,"medical_device_id":19,"response_letter_date":19},1474,[81,82,83,84,85,13,13,13],"\u003Ctime datetime=\"2024-05-07T13:20:00Z\">05\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-03T04:00:00Z\">04\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbioptimal-international-678281-04032024\">Bioptimal International\u003C\u002Fa>","&quot;OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality&quot;","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Lai Chunhong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Group CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bioptimal International\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3A, Unit 1, Building F, Tianebao (Stage Two), No. 2, Xiangshan Middle Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nanshan Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 678281\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 3, 2024\u003Cbr>\n\u003Cbr>\nDear Ms. Chunhong:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Singapore, Southwest on November 6, 2023 through November 11, 2023 an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Thermodilution Catheter and Pulmonary Artery Monitoring Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter is a correction to the letter issued on April 3, 2024. It communicates identical issues but utilizes the FDA letterhead.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved Device Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You currently have a clearance for the 'Thermodilution Catheter under K101669. Our inspection revealed that your firm made changes to the materials of the cleared device, including removal of the polyvinylchloride (PVC) tubing heparin coating, without submission of a new 510(k) premarket notification. This change could significantly affect the safety or effectiveness of the device and requires the submission of a new 510(k) premarket notification 21 CFR 807.81(a)(3)(i). For example, removal of this coating can increase friction in the tubing and negatively impact the thrombogenicity profile of the device.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> This can lead to increased blood clotting and\u002For thrombus, which can result in embolization during clinical use, significantly impacting patient safety.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm is marketing a Pulmonary Artery Catheter and claiming this device maintains the same device design as the cleared Thermodilution Catheter (K101669). However, based on the information gathered during the inspection, it appears the Pulmonary Artery Catheter has several technological characteristics that differ from the cleared Thermodilution Catheter. The 510(k) Summary for the Thermodilution catheter states that the device maintains a 4- and 5-lumen design with the extension and includes a thermistor. The Pulmonary Catheter is noted to include a 2- and 3-lumen configuration and does not maintain a thermistor element. Modification to the lumen design and removal of the thermistor change structural device properties and the ability to perform functions such as providing accurate measurements of body temperature during clinical use. Without proper evaluation to demonstrate the device continues to perform to appropriate standards, there is a higher risk of device failure during use, which can significantly impact patient safety. Considering this, a submission of a new 510(k) premarket notification is required according to 21 CFR 807.81(a)(3)(i).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Accordingly, both the Thermodilution Catheter and the Pulmonary Artery Monitoring Catheter devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for either device. The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated November 30, 2023, concerning our investigator's observations noted on the Form FDA 483, List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a) and (d). For example:\u003C\u002Fp>\n\n\u003Cp>The complaint handling procedure, BQS-005, does not require that any incoming complaint be evaluated to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803, Medical Device Reporting (MDR). Further, your firm did not review, evaluate, and investigate certain complaints in a timely manner to determine whether they represent an event which must be reported to FDA under 21 CFR part 803, and such complaints did not include the appropriate records including the name of the device, the date the complaint was received, the Unique Device Identifier (UDI), and the name, address, and phone number of the complainant. We also note that your firm's complaint handling procedures do not require that complaint investigation records include the required information above.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined at this time because your corrective actions are not yet complete. In your response you state your planned corrective action includes a retrospective review of adverse events to determine MDR reportability, including completeness of adverse event report records, and revision of complaint record procedure to ensure UDI compliance. You stated your corrective actions will be completed by February and March of 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your complaint record procedure and any associated evidence of the corrective actions.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action (CAPA), specifically, verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\n\n\u003Cp>Some procedures of your firm's corrective and preventive actions, BQS-004 and BQS-005, have not been clearly established and your firm is not consistent with compliance\u002Ffollow-through when it initiates corrective actions. Specifically, your firm has not demonstrated consistent collection of evidence of the completion of previous corrective actions, and your firm lacks procedures for verification or validation of effectiveness conducted after corrective action. In addition, there have been instances where quality data sources indicated data trends, including two or more complaints from the same lot reporting similar failure modes and\u002For device malfunctioning, which were not investigated further (i.e., no corrective action was taken even though the complaint handling documents required otherwise). Lastly, your firm failed to take corrective action when the actual occurrence rates of several device failure modes exceeded the anticipated occurrence rates specified in the risk management file for the Thermodilution Catheter.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response, you state your planned corrective action plan includes updating current CAPA procedures to include new device risk assessments and escalating all complaints from different SOP sources. In addition, you plan to initiate CAPAs for current customer complaints to provide resolution retrospectively. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the newly updated CAPA procedures and details\u002Fstrategy for initiating CAPAs for current customer complaints.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to validate device design to ensure that devices conform to defined user needs and intended uses, and include risk analysis where appropriate, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's risk analysis procedures are inadequate. The actual occurrence rate of several device failure modes exceeded the anticipated occurrence rates that were specified in the risk management file and your firm did not take appropriate action. Further, your firm's risk analysis plan, BQS-006, specifies that the risk management file be reviewed and updated annually following an analysis of risks related to customer complaints and other items. The main device under consideration for repeated device failure is the Thermodilution Catheter and accessories. The failures include balloon rupture, balloon deflation difficulty, balloon inflation problems, pressure measurement issue, and cardiac output measurement issue. A device change was made to remove the heparin coating from the catheter shaft of the tubing and there was not documented assessment of the impact of friction resistance related to this change.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response you state your planned corrective action includes updating the risk assessment report for the Thermodilution Catheter, Pulmonary Artery Catheter, and Biotray to account for the number of device failures. In addition, you state that friction resistance testing will be conducted using non-coated tubing materials for the Thermodilution Catheter. You state your corrective actions will be completed by March 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide your updated documentation including, but not limited to, the revised versions of your risk management file with updated device failures for your devices. Please refer to the \"Unapproved Device Violation\" section above and provide the friction resistance testing as part of a new 510(k) premarket notification.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm has not established procedures to conduct sterilization process validation. Without these procedures, your firm has not specified requirements to validate sterilization processes, instructions on testing frequency, and instructions for requalification of sterilization activities. Your firm also does not have a set plan for monitoring and controlling process parameters to ensure that sterilization specifications are met.\u003C\u002Fp>\n\n\u003Cp>Your response dated November 30, 2023, does not completely address this observation. In your response you state your planned corrective action includes establishing and creating a sterilization process validation procedure according to the current practice and sterilization method employed. You also plan to send the new QA staff for process validation concepts and awareness external training. You state your corrective actions will be completed by January 2024, but FDA has not received this information by the date of this letter. In your response to this Warning letter, you should provide updated documentation including, but not limited to, the revised versions of your sterilization validation procedure and QA staff training certification. Further, your response is not adequate because you have not indicated that you will perform validation where appropriate to determine whether action is needed for product already distributed under these procedures.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain device history record (DHR) procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184(e) and (f). For example:\u003C\u002Fp>\n\n\u003Cp>Your firm has not established complete procedures to track device history records (DHR). Specifically, the currently established DHRs do not include or refer to where information regarding the primary identification label for each product unit and the unique device identifier can be found.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined at this time as your corrective actions are not yet complete. In your response you state your planned corrective actions include revision and updating of the DHR work instruction to include the CFR reporting requirements and primary packaging label with the UDI. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In your response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your DHR work instruction and updated primary packaging labels with the device UDI.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Reporting Violation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm's Thermodilution Catheter device is misbranded under section 502(0(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the document titled \"Vigilance reporting and recalls\u002FFSCA for USFDA\", BPI-WI-010, Rev. 01, dated 10\u002F26\u002F2023 as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\n\n\u003Cp>The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>a) The procedure includes the definition from 21 CFR 803.3 for the terms \"MDR reportable event\", \"become aware\", \"caused or contributed\", \"malfunction\", and \"serious injury\". However, the procedure does not provide clear guidance to staff on how they should determine if information \"reasonably suggests\" that an event should be reported. Refer to the definition of the term \"reasonably suggests\" found in 21 CFR 803.20(c)(1). The exclusion of such information from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\n\n\u003Cp>b) The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\u003C\u002Fp>\n\n\u003Cp>c) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include a process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive.\u003C\u002Fp>\n\n\u003Cp>d) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\u003Cbr>\n&nbsp; a. Documentation of adverse event related information maintained as MDR event files.\u003Cbr>\n&nbsp; b. Information that was evaluated to determine if an event was reportable.\u003Cbr>\n&nbsp; c. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated November 30, 2023, cannot be determined at this time. In the response, your firm outlined a plan to address each identified deficiency, including projected completion dates. However, as these corrective actions are still in progress, there is no documentation or evidence available yet to confirm their completion.\u003C\u002Fp>\n\n\u003Cp>2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\u003C\u002Fp>\n\n\u003Cp>The information included for Complaint CCS23-04-025 reasonably suggests that a patient sustained an injury that resulted in a thrombus, after a procedure using your firm's Central Venous Catheter. This condition necessitated drug treatment. In the absence of the information indicating the contrary, we believe that the drug treatment was necessitated to prevent permanent impairment of a body function or damage to a body structure. Therefore, the information included in the complaint reasonably suggests a serious injury for which an MDR must be submitted. Your firm became aware of this event on March 24, 2023. However, an MDR for the corresponding event has not yet been received by FDA.\u003C\u002Fp>\n\n\u003Cp>Your firm's response dated November 30, 2023, did not address the noted violation as the issue was not included in the FDA Form 483. In response to this Warning Letter, you should provide documentation to address this identified violation.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent by email to CDRHWarningLetterResponsesafda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. \u003Cstrong>Refer to CMS case #678281 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: Lydia S. Glaw, Ph.D. at 301-796-1456.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Bram Zuckerman\u003Cbr>\nDr. Bram Zuckerman\u003Cbr>\nDirector\u003Cbr>\nOHT 2: Office of Cardiovascular Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nDennis Bassett\u003Cbr>\nBIOMEDICAL SALES INTERNATIONAL, INC.\u003Cbr>\n457 W Virginia Ave\u003Cbr>\nPunta Gorda, FL US 33950\u003Cbr>\nPhone: 513 2586555 Ext\u003Cbr>\nFax: 513 7728388\u003Cbr>\nEmail: Dwbassett@Cs.Com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> In October 2017, FDA published the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device (\"510(k) Modifications Guidance\"), which provided FDA's current thinking to enhance the predictability, consistency, and transparency of the when a change in a medical device would trigger the requirement that a manufacturer submit a new 510(k) premarket notification to the Agency. \u003Cem>Available\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatorv-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device. As explained in Section C.4.1 of the guidance, in general, changing the material or device design may affect the performance testing of the device.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> As explained in Section B.5 of the 510(k) Modification Guidance, in general, changing the device design (e.g., dimensional and component changes) may result in new technological characteristics that raise different questions of safety and effectiveness.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMs. Lai Chunhong\n\nRecipient Title\n\nGroup CEO\n\nBioptimal International\n\n3A, Unit 1, Building F, Tianebao (Stage Two), No. 2, Xiangshan Middle Street\n\nNanshan Qu\n\nShenzhen Shi\n\nGuangdong Sheng,\n\nChina\n\nIssuing Office:\n\n\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"\n\nUnited States\n\nWARNING LETTER\n\nCMS # 678281\n\nApril 3, 2024\n\nDear Ms. Chunhong:\n\nDuring an inspection of your firm located in Singapore, Southwest on November 6, 2023 through November 11, 2023 an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Thermodilution Catheter and Pulmonary Artery Monitoring Catheter. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter is a correction to the letter issued on April 3, 2024. It communicates identical issues but utilizes the FDA letterhead.\n\nUnapproved Device Violation\n\nYou currently have a clearance for the 'Thermodilution Catheter under K101669. Our inspection revealed that your firm made changes to the materials of the cleared device, including removal of the polyvinylchloride (PVC) tubing heparin coating, without submission of a new 510(k) premarket notification. This change could significantly affect the safety or effectiveness of the device and requires the submission of a new 510(k) premarket notification 21 CFR 807.81(a)(3)(i). For example, removal of this coating can increase friction in the tubing and negatively impact the thrombogenicity profile of the device.1 This can lead to increased blood clotting and\u002For thrombus, which can result in embolization during clinical use, significantly impacting patient safety.\n\nOur inspection also revealed that your firm is marketing a Pulmonary Artery Catheter and claiming this device maintains the same device design as the cleared Thermodilution Catheter (K101669). However, based on the information gathered during the inspection, it appears the Pulmonary Artery Catheter has several technological characteristics that differ from the cleared Thermodilution Catheter. The 510(k) Summary for the Thermodilution catheter states that the device maintains a 4- and 5-lumen design with the extension and includes a thermistor. The Pulmonary Catheter is noted to include a 2- and 3-lumen configuration and does not maintain a thermistor element. Modification to the lumen design and removal of the thermistor change structural device properties and the ability to perform functions such as providing accurate measurements of body temperature during clinical use. Without proper evaluation to demonstrate the device continues to perform to appropriate standards, there is a higher risk of device failure during use, which can significantly impact patient safety. Considering this, a submission of a new 510(k) premarket notification is required according to 21 CFR 807.81(a)(3)(i).2\n\nAccordingly, both the Thermodilution Catheter and the Pulmonary Artery Monitoring Catheter devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for either device. The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fdevice-advice-comprehensive-regulatory-assistance\u002Fhow-study-and-market-your-device. The FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\n\nQuality System Violations\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated November 30, 2023, concerning our investigator's observations noted on the Form FDA 483, List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a) and (d). For example:\n\nThe complaint handling procedure, BQS-005, does not require that any incoming complaint be evaluated to determine whether the complaint represents an event which is required to be reported to FDA under 21 CFR 803, Medical Device Reporting (MDR). Further, your firm did not review, evaluate, and investigate certain complaints in a timely manner to determine whether they represent an event which must be reported to FDA under 21 CFR part 803, and such complaints did not include the appropriate records including the name of the device, the date the complaint was received, the Unique Device Identifier (UDI), and the name, address, and phone number of the complainant. We also note that your firm's complaint handling procedures do not require that complaint investigation records include the required information above.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined at this time because your corrective actions are not yet complete. In your response you state your planned corrective action includes a retrospective review of adverse events to determine MDR reportability, including completeness of adverse event report records, and revision of complaint record procedure to ensure UDI compliance. You stated your corrective actions will be completed by February and March of 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your complaint record procedure and any associated evidence of the corrective actions.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive action (CAPA), specifically, verifying or validating the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a). For example:\n\nSome procedures of your firm's corrective and preventive actions, BQS-004 and BQS-005, have not been clearly established and your firm is not consistent with compliance\u002Ffollow-through when it initiates corrective actions. Specifically, your firm has not demonstrated consistent collection of evidence of the completion of previous corrective actions, and your firm lacks procedures for verification or validation of effectiveness conducted after corrective action. In addition, there have been instances where quality data sources indicated data trends, including two or more complaints from the same lot reporting similar failure modes and\u002For device malfunctioning, which were not investigated further (i.e., no corrective action was taken even though the complaint handling documents required otherwise). Lastly, your firm failed to take corrective action when the actual occurrence rates of several device failure modes exceeded the anticipated occurrence rates specified in the risk management file for the Thermodilution Catheter.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response, you state your planned corrective action plan includes updating current CAPA procedures to include new device risk assessments and escalating all complaints from different SOP sources. In addition, you plan to initiate CAPAs for current customer complaints to provide resolution retrospectively. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide updated documentation including, but not limited to, the newly updated CAPA procedures and details\u002Fstrategy for initiating CAPAs for current customer complaints.\n\n3. Failure to establish and maintain procedures to validate device design to ensure that devices conform to defined user needs and intended uses, and include risk analysis where appropriate, as required by 21 CFR 820.30(g). For example:\n\nYour firm's risk analysis procedures are inadequate. The actual occurrence rate of several device failure modes exceeded the anticipated occurrence rates that were specified in the risk management file and your firm did not take appropriate action. Further, your firm's risk analysis plan, BQS-006, specifies that the risk management file be reviewed and updated annually following an analysis of risks related to customer complaints and other items. The main device under consideration for repeated device failure is the Thermodilution Catheter and accessories. The failures include balloon rupture, balloon deflation difficulty, balloon inflation problems, pressure measurement issue, and cardiac output measurement issue. A device change was made to remove the heparin coating from the catheter shaft of the tubing and there was not documented assessment of the impact of friction resistance related to this change.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined because your corrective actions are not yet complete. In your response you state your planned corrective action includes updating the risk assessment report for the Thermodilution Catheter, Pulmonary Artery Catheter, and Biotray to account for the number of device failures. In addition, you state that friction resistance testing will be conducted using non-coated tubing materials for the Thermodilution Catheter. You state your corrective actions will be completed by March 2024, but FDA has not received this information by the date of this letter. In response to this Warning Letter, you should provide your updated documentation including, but not limited to, the revised versions of your risk management file with updated device failures for your devices. Please refer to the \"Unapproved Device Violation\" section above and provide the friction resistance testing as part of a new 510(k) premarket notification.\n\n4. Failure to adequately ensure that when the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75. For example:\n\nYour firm has not established procedures to conduct sterilization process validation. Without these procedures, your firm has not specified requirements to validate sterilization processes, instructions on testing frequency, and instructions for requalification of sterilization activities. Your firm also does not have a set plan for monitoring and controlling process parameters to ensure that sterilization specifications are met.\n\nYour response dated November 30, 2023, does not completely address this observation. In your response you state your planned corrective action includes establishing and creating a sterilization process validation procedure according to the current practice and sterilization method employed. You also plan to send the new QA staff for process validation concepts and awareness external training. You state your corrective actions will be completed by January 2024, but FDA has not received this information by the date of this letter. In your response to this Warning letter, you should provide updated documentation including, but not limited to, the revised versions of your sterilization validation procedure and QA staff training certification. Further, your response is not adequate because you have not indicated that you will perform validation where appropriate to determine whether action is needed for product already distributed under these procedures.\n\n5. Failure to establish and maintain device history record (DHR) procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record, as required by 21 CFR 820.184(e) and (f). For example:\n\nYour firm has not established complete procedures to track device history records (DHR). Specifically, the currently established DHRs do not include or refer to where information regarding the primary identification label for each product unit and the unique device identifier can be found.\n\nThe adequacy of your response dated November 30, 2023, cannot be determined at this time as your corrective actions are not yet complete. In your response you state your planned corrective actions include revision and updating of the DHR work instruction to include the CFR reporting requirements and primary packaging label with the UDI. You state your corrective actions will be completed by February 2024, but FDA has not received this information by the date of this letter. In your response to this Warning Letter, you should provide updated documentation including, but not limited to, the revised version of your DHR work instruction and updated primary packaging labels with the device UDI.\n\nMedical Device Reporting Violation\n\nOur inspection also revealed that your firm's Thermodilution Catheter device is misbranded under section 502(0(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\n1. Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17. For example, during the inspection, your firm identified the document titled \"Vigilance reporting and recalls\u002FFSCA for USFDA\", BPI-WI-010, Rev. 01, dated 10\u002F26\u002F2023 as its written MDR procedure. After reviewing the procedure, the following deficiencies were noted:\n\nThe procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example:\n\na) The procedure includes the definition from 21 CFR 803.3 for the terms \"MDR reportable event\", \"become aware\", \"caused or contributed\", \"malfunction\", and \"serious injury\". However, the procedure does not provide clear guidance to staff on how they should determine if information \"reasonably suggests\" that an event should be reported. Refer to the definition of the term \"reasonably suggests\" found in 21 CFR 803.20(c)(1). The exclusion of such information from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\n\nb) The procedure, as written, combines language from the requirements of other regulatory or competent authorities with the requirements in 21 CFR Part 803 in a manner that will result in incomplete, inadequate, or even non-reporting of adverse events that meet the reportability requirements under 21 CFR Part 803.\n\nc) The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include a process for submitting initial and supplement or follow-up reports to FDA in an electronic format that FDA can process, review and archive.\n\nd) The procedure does not describe how your firm will address documentation and recordkeeping requirements, as required by 21 CFR 803.17(b), including:\n\na. Documentation of adverse event related information maintained as MDR event files.\n\nb. Information that was evaluated to determine if an event was reportable.\n\nc. Documentation of the deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable, as required under 21 CFR 803.18(b)(1)(i).\n\nThe adequacy of your response dated November 30, 2023, cannot be determined at this time. In the response, your firm outlined a plan to address each identified deficiency, including projected completion dates. However, as these corrective actions are still in progress, there is no documentation or evidence available yet to confirm their completion.\n\n2. Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\n\nThe information included for Complaint CCS23-04-025 reasonably suggests that a patient sustained an injury that resulted in a thrombus, after a procedure using your firm's Central Venous Catheter. This condition necessitated drug treatment. In the absence of the information indicating the contrary, we believe that the drug treatment was necessitated to prevent permanent impairment of a body function or damage to a body structure. Therefore, the information included in the complaint reasonably suggests a serious injury for which an MDR must be submitted. Your firm became aware of this event on March 24, 2023. However, an MDR for the corresponding event has not yet been received by FDA.\n\nYour firm's response dated November 30, 2023, did not address the noted violation as the issue was not included in the FDA Form 483. In response to this Warning Letter, you should provide documentation to address this identified violation.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent by email to CDRHWarningLetterResponsesafda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #678281 when replying. If you have any questions about the contents of this letter, please contact: Lydia S. Glaw, Ph.D. at 301-796-1456.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nBram Zuckerman\n\nDr. Bram Zuckerman\n\nDirector\n\nOHT 2: Office of Cardiovascular Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nDennis Bassett\n\nBIOMEDICAL SALES INTERNATIONAL, INC.\n\n457 W Virginia Ave\n\nPunta Gorda, FL US 33950\n\nPhone: 513 2586555 Ext\n\nFax: 513 7728388\n\nEmail: Dwbassett@Cs.Com\n\n______________________\n\n1 In October 2017, FDA published the guidance document Deciding When to Submit a 510(k) for a Change to an Existing Device (\"510(k) Modifications Guidance\"), which provided FDA's current thinking to enhance the predictability, consistency, and transparency of the when a change in a medical device would trigger the requirement that a manufacturer submit a new 510(k) premarket notification to the Agency. Available at https:\u002F\u002Fwww.fda.gov\u002Fregulatorv-information\u002Fsearch-fda-guidance-documents\u002Fdeciding-when-submit-510k-change-existing-device. As explained in Section C.4.1 of the guidance, in general, changing the material or device design may affect the performance testing of the device.\n\n2 As explained in Section B.5 of the 510(k) Modification Guidance, in general, changing the device design (e.g., dimensional and component changes) may result in new technological characteristics that raise different questions of safety and effectiveness.","Bioptimal International","bioptimal-international-678281-04032024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbioptimal-international-678281-04032024","2026-10-26T08:08:05.402825+00:00","2024-05-07","678281","\"OHT2: Office of Cardiovascular Devices, Office of Product Evaluation and Quality\"","Ms. Lai Chunhong","2026-08-20T00:06:56.589+00:00","2024-04-03",{"id":100,"raw":101,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":110,"fei_number":19,"letter_url":111,"updated_at":112,"action_type":22,"case_status":23,"posted_date":113,"marcs_cms_no":114,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":115,"body_fetched_at":116,"delivery_method":117,"recipient_title":19,"reference_number":118,"action_taken_date":119,"medical_device_id":19,"response_letter_date":19},274,[102,103,104,36,105,13,13,13],"\u003Ctime datetime=\"2026-03-10T04:00:00Z\">03\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsimtra-biopharma-solutions-720436-03032026\">Simtra BioPharma Solutions\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-49\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Franco Negron\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Simtra BioPharma Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Building C, Suite 270, 2nd Floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>400 Interpace Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Parsippany\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:frnegron@simtra.com\"> frnegron@simtra.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-49\u003C\u002Fp>\u003Cp>March 3, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Negron:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) conducted an unannounced inspection of your drug manufacturing facility, Simtra Deutschland GmbH, formerly Baxter Oncology GmbH, FEI 3002806419, at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, from September 18 to 26, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 20, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant deficiencies were identified with aseptic processing controls in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and restricted access barrier system (RABS) processing lines used to aseptically manufacture sterile drug products for the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cem>Cleaning and Disinfection\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You used \u003Cstrong>(b)(4)\u003C\u002Fstrong> extensively to rinse critical, interior surfaces and aseptic processing equipment in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS lines after production. This \u003Cstrong>(b)(4)\u003C\u002Fstrong> was fed from \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use points inside your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS through excessively long (up to approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>) deadlegs from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> loop. Deadlegs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> systems are known to cause stagnation of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and excessive microbial growth.\u003C\u002Fp>\u003Cp>Between June 2023 and September 2025, routine testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use points in your ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS resulted in at least 47 microbial recoveries, including 14 that exceeded your action limit. Your routine monitoring samples repeatedly recovered gram-negative, biofilm-forming, \u003Cstrong>(b)(4)\u003C\u002Fstrong> organisms including \u003Cem>Sphingomonas, Methylobacterium, Bradyrhizobium\u003C\u002Fem>, and \u003Cem>Ralstonia\u003C\u002Fem> species. Investigations for at least two incidents associated with microbial recoveries identified the design of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use point piping as the most likely root cause. However, your corrective action and preventive action (CAPA) plans have failed to comprehensively address the identified deficiencies in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design.\u003C\u002Fp>\u003Cp>Furthermore, post-production environmental monitoring (EM) samples taken within your ISO 5 \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS between June 2023 and September 2025 have resulted in repeated recoveries of gram-negative \u003Cstrong>(b)(4)\u003C\u002Fstrong> organisms including \u003Cem>Sphingomonas, Methylobacterium\u003C\u002Fem>, and \u003Cem>Cupriavidus\u003C\u002Fem> species.\u003C\u002Fp>\u003Cp>This sampling identified a worrisome adverse trend in your RABS in late 2023 in which \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were found to be contaminated with gram negative microbes. Significantly, too-numerous-to-count (TNTC) levels were present on RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets in multiple instances during this period. Your investigations acknowledged that equipment design (including \u003Cstrong>(b)(4)\u003C\u002Fstrong> gaskets) and maintenance, in combination with cleaning (e.g., residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> from cleaning), caused the deviation.\u003C\u002Fp>\u003Cp>You failed to sufficiently address the underlying cause of residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> in a timely manner, instead relying on personnel to \u003Cstrong>(b)(4)\u003C\u002Fstrong> dry any observed moisture.\u003C\u002Fp>\u003Cp>In your response, you commit to corrective actions including \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning use point piping and \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in ISO 5 cleaning. Additionally, you explain your process of \u003Cstrong>(b)(4)\u003C\u002Fstrong>-drying your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS with \u003Cstrong>(b)(4)\u003C\u002Fstrong> drying of residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> during visual inspection by operators. You also commit to implementing \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS.\u003C\u002Fp>\u003Cp>Your response is inadequate because your corrective actions fail to address the fundamental, self-identified design flaw in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> supply lines” that lead to each of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS processing lines for cleaning. You also fail to holistically address residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> from cleaning your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS units across your site. The residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> issue poses a significant risk to barrier\u002F\u003Cstrong>(b)(4)\u003C\u002Fstrong> system control (e.g., interference with decontamination cycle efficacy) and can potentially lead to drug product contamination.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Integrity Testing\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately maintain equipment to assure aseptic conditions. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program for \u003Cstrong>(b)(4)\u003C\u002Fstrong> was found to be deficient. For example:\u003C\u002Fp>\u003Cul>\u003Cli>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program for \u003Cstrong>(b)(4)\u003C\u002Fstrong> permitted \u003Cstrong>(b)(4)\u003C\u002Fstrong> to fail acceptance criteria during pressure decay testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> times before requiring replacement. Your translated procedure states, “All \u003Cstrong>(b)(4)\u003C\u002Fstrong> that fail the leak test (pressure drop test) may be retested. If the \u003Cstrong>(b)(4)\u003C\u002Fstrong> fails more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> times, it must be replaced.”\u003C\u002Fli>\u003Cli>When \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed leak testing, retesting was often not performed the same day but at a later date. As a result, you manufactured drug products using \u003Cstrong>(b)(4)\u003C\u002Fstrong> that had failed leak testing without confirming their integrity. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> on line \u003Cstrong>(b)(4)\u003C\u002Fstrong> failed to meet acceptance criteria on July 1, 2025, and did not pass testing until July 19, 2025. In the 18-day period between these tests, your production schedule indicated you manufactured at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of drug products.\u003C\u002Fli>\u003Cli>You lacked raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data. During the inspection, you were unable to locate raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing data from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for line \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Instead of reviewing raw \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data, your quality assurance unit relied on forms containing transcribed information.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you commit to enhancing your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program through procedural updates requiring additional quality oversight, defining actions following test failures including not permitting production to proceed “following an invalid or failed test,” and implementing quality review of visual and \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing results.\u003C\u002Fp>\u003Cp>You indicate that inappropriate acceptance criteria programmed into your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing device caused many of the failures. You also assert, “[T]here has been no impact to any released batches or the overall control of sterility assurance at the site.”\u003C\u002Fp>\u003Cp>Furthermore, your response states that in your operators’ experience, pressure decay failures are generally not indicative of non-integral \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and they instead relied upon visual inspection.\u003C\u002Fp>\u003Cp>Your response calls into question the reliability of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing program. Visual inspections, on their own, are insufficient to monitor \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity. Visual \u003Cstrong>(b)(4)\u003C\u002Fstrong> examinations provide far lower detectability than, and cannot be substituted for, \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing devices. It is essential that your firm use \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity testing devices that are capable of reliably detecting sub-visible breaches in \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity.\u003C\u002Fp>\u003Cp>You also failed to perform retrospective evaluation of potentially impacted products and processes. In response to the uninvestigated \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity failures, you concluded there was no quality impact to released batches or overall contamination risk at the site. However, you appear to have limited your review only to examples cited during the inspection.\u003C\u002Fp>\u003Cp>Additionally, you failed to assess equipment management across your site to identify other potentially impacted critical equipment that may affect aseptic conditions. You should give continual attention to the integrity of critical equipment. This includes comprehensive maintenance procedures that establish adequate integrity testing and proactive replacement before breakdown.\u003C\u002Fp>\u003Cp>\u003Cem>Protective Equipment Materials\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to implement other adequate equipment control systems to prevent contamination during aseptic processing. Our investigators observed particles shedding from \u003Cstrong>(b)(4)\u003C\u002Fstrong> material in aseptic areas. For example, loose, visible fibers were observed on and dislodging from \u003Cstrong>(b)(4)\u003C\u002Fstrong> covers during \u003Cstrong>(b)(4)\u003C\u002Fstrong> installation within critical aseptic filling areas. Fibers also were observed on tubing in two locations in line \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Subsequently, unused \u003Cstrong>(b)(4)\u003C\u002Fstrong> covers were inspected and observed to have loose fibers indicating the material itself was the source of contamination. You use the material is used to protect \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the end of sterile tubing.\u003C\u002Fp>\u003Cp>Furthermore, this is an ongoing issue. Your customer reported your previous non-pharmaceutical grade \u003Cstrong>(b)(4)\u003C\u002Fstrong> material as a source of particulate contamination. In response, you introduced your current \u003Cstrong>(b)(4)\u003C\u002Fstrong> material across your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS processing lines without evaluating its particle generating characteristics.\u003C\u002Fp>\u003Cp>In your response, you explain the \u003Cstrong>(b)(4)\u003C\u002Fstrong> seams on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> are the apparent source of visible fibers and they appear to be statically charged. You also indicate you are working with your supplier to address this issue while taking interim controls including awareness training, visual checks of equipment at risk of fibers, removal of observed fibers with sterile lint-free wipes, and the exchange of equipment when fibers are observed attached to product contact surfaces.\u003C\u002Fp>\u003Cp>Your response is inadequate. You limited your retrospective batch review to only the two batches observed to be exposed to loose fibers during the inspection. Your response also fails to assess the particles generated by the \u003Cstrong>(b)(4)\u003C\u002Fstrong> material to determine their characteristics (e.g., size). Additionally, your response fails to support the adequacy of visual inspection as an interim control or to review quality indicators for particle related issues (e.g., complaints, deviations). Finally, your response did not address your failure to evaluate particle generation in the replacement material when you implemented a change control for \u003Cstrong>(b)(4)\u003C\u002Fstrong> in response to a particle generation complaint. This is a quality oversight failure.\u003C\u002Fp>\u003Cp>Aseptic processing operations should be designed and executed to minimize exposure of sterile articles to potential contamination hazards in the manufacturing operation. Flaws in the design of cleanrooms and aseptic processing lines or improper execution of aseptic operations can enable entry of contaminants into the critical (ISO 5) processing area and lead to product contamination.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> technology represents a significant advance over traditional operational designs. However, all technologies have failure modes that require ongoing, vigilant monitoring and maintenance to ensure a state of control, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A strong quality system is essential to oversee design and construction of aseptic processing lines and supporting utilities, and to ensure ongoing proper operational control to safeguard against contamination hazards throughout the facility lifecycle.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design, control, and maintenance including, but not limited to:\u003Cbr>o Identification of deadlegs and any other insanitary elements of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003Cbr>o A comprehensive remediation plan and detailed CAPA timeline for improving design, control, and maintenance of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Include re-piping and modifications to eliminate deadlegs, removal of insanitary fittings, assurance of appropriately designed recirculating loops, and completion of all other needed remediations to ensure sanitary systems. Place special emphasis on identifying and eliminating any deadlegs that feed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, RABS, or other sterile production equipment.\u003Cbr>o The validation report for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system after all identified design issues have been fully corrected and any maintenance repairs have been completed. Include the system validation protocol, the complete test results, and the final validation report. Include the summary of all improvements made to system design, as well as the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of potential contamination from residual moisture after cleaning. For each production line, assess \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning and \u003Cstrong>(b)(4)\u003C\u002Fstrong> drying cycles, identify specific equipment parts which remain within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS after cleaning, and address the potential for \u003Cstrong>(b)(4)\u003C\u002Fstrong> to remain stagnant within equipment between production operations. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture products intended to be sterile.\u003C\u002Fli>\u003Cli>Based upon the cleaning effectiveness assessment, provide a CAPA detailing improvements to your cleaning and disinfection program including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning and disinfection execution for all products and equipment, and all other needed remediations.\u003C\u002Fli>\u003Cli>A comprehensive assessment of the design and control of your firm’s manufacturing operations with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A comprehensive evaluation of your ongoing \u003Cstrong>(b)(4)\u003C\u002Fstrong> maintenance program.\u003Cbr>o Address elements including, but not limited to, frequency of integrity tests (e.g., at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>), \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedure and methodology, and appropriate practices to reduce the occurrence of invalid tests.\u003Cbr>o Conduct an analysis of the various failure scenarios that have occurred during your \u003Cstrong>(b)(4)\u003C\u002Fstrong> leak testing (e.g., device set-up problems, failure to meet initial pressure, employee interference). Also include further clarity on whether supervisors will be notified immediately, prior to initiation of a retest, of any instance of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> integrity test failure.\u003Cbr>o Include a product impact assessment.\u003Cbr>o Provide associated CAPA.\u003C\u002Fli>\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities. A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A risk assessment addressing the use of shedding material within your critical ISO 5 production areas. Include a detailed summary of how you determined that your interim controls are adequate to prevent the contamination of products. Include details of your investigation such as evaluation of particle generation, particle size distribution, and the likelihood of detection by visual inspection. Discuss your investigation into potentially impacted lots of product including your evaluation of quality indicators such as complaints and deviations. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles were inadequately validated to ensure that they were capable of consistently decontaminating all interior surfaces of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and multiple RABS lines in preparation for aseptic production.\u003C\u002Fp>\u003Cp>\u003Cem>Biological Indicator Recoveries\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Inadequacies in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> process were demonstrated through a trend of routine recoveries of biological indicator (BI) growth at completion of validation cycles executed in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> since 2022.\u003C\u002Fp>\u003Cp>Notably, your acceptance criteria were inappropriate in that they allowed routine recovery of multiple BI survivors. For example, positive BIs (upwards of 8 recoveries) were identified in nearly all validation cycles (\u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) between 2022 and 2025 on your lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> lines. These positive BIs occurred at various locations within each line. However, based upon your inappropriate acceptance criteria, only two of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation cycles were found to be unacceptable.\u003C\u002Fp>\u003Cp>Furthermore, you attributed recent validation failures in 2025 to “rogue” phenomenon in a BI lot, but this fails to recognize the multiple positive BIs that occurred with other BI lots in the same year. You also failed to acknowledge your long-term trend of routine BI positives in most of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation studies.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation did not demonstrate reliable decontamination cycle capability. For example:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> were not \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation cycles such that \u003Cstrong>(b)(4)\u003C\u002Fstrong> were present in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your validation instruction, PPVA VA 48074e\u002F03, appears to permit \u003Cstrong>(b)(4)\u003C\u002Fstrong> to rest on the bottom of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, creating an occluded surface which undermines the ability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to decontaminate this critical location.\u003C\u002Fli>\u003Cli>You did not document or adequately specify each location of BI placement. You also lacked scientific evidence to support the triplicate BIs being representative of each location.\u003C\u002Fli>\u003Cli>You allowed repetition of validation cycles without proper investigation in each instance of observed BI growth. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> validation cycle was repeated in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> after initially failing to meet its acceptance criteria for positive BIs (\u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you committed to assessing your \u003Cstrong>(b)(4)\u003C\u002Fstrong> for surface exposure and implementing remediations based on your findings where possible, increasing BIs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> with \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process validation, updating your procedures to address failed validation cycles, reducing the allowable BI growth, implementing investigational requirements for any BI growth, and optimizing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle in your \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. You failed to address multiple years of consistent recoveries of positive BIs across multiple locations within your \u003Cstrong>(b)(4)\u003C\u002Fstrong> during previous validation cycles. Recurrent failures are indicative of poor cycle robustness and require further investigation. Furthermore, your commitment to increase the number of BIs in \u003Cstrong>(b)(4)\u003C\u002Fstrong> does not address setup and configuration adaptations that can ensure consistent exposure of all interior surfaces to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Incomplete exposure of interior surfaces to \u003Cstrong>(b)(4)\u003C\u002Fstrong> compromises decontamination effectiveness and places the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS environment at risk. Furthermore, as discussed above, the inconsistent removal of residual moisture prior to \u003Cstrong>(b)(4)\u003C\u002Fstrong> treatment of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and RABS could further compromise \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination efficacy.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of variation to ensure a continuing state of control.&nbsp;\u003C\u002Fli>\u003Cli>A comprehensive, independent review of the adequacy of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles. Place special attention on \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle stages including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Provide a timeline for a detailed report on the findings of the independent review and associated CAPA activities (e.g., cycle parameter changes such as an increased decontamination phase duration; optimized airflow; improved surface exposure).\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your decontamination cycles that includes vigilant monitoring to ensure an ongoing state of control. Also, include your program for assuring ongoing state of control throughout your facility and equipment infrastructure.\u003C\u002Fli>\u003Cli>Procedures to ensure residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> is appropriately removed from RABS and \u003Cstrong>(b)(4)\u003C\u002Fstrong> units before execution of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Request for a Meeting with FDA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>After you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your corrective actions and preventive actions in detail. Please direct your request to Patricia Warren at patricia.warren@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Simtra Deutschland GmbH located at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806419 and ATTN: Samantha Bradley.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Rémi Helmig\u003Cbr>Site Director\u003Cbr>Simtra Deutschland GmbH\u003Cbr>Kantstr. 2\u003Cbr>33790 Halle\u002FWestphalia\u003Cbr>Germany\u003Cbr>rhelmig@simtra.com\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-26-49\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nFranco Negron\n\nRecipient Title\n\nChief Executive Officer\n\nSimtra BioPharma Solutions\n\nBuilding C, Suite 270, 2nd Floor\n\n400 Interpace Parkway\n\nParsippany, NJ 07054\n\nUnited States\n\nfrnegron@simtra.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-49\nMarch 3, 2026\nDear Mr. Negron:\nThe United States Food and Drug Administration (FDA) conducted an unannounced inspection of your drug manufacturing facility, Simtra Deutschland GmbH, formerly Baxter Oncology GmbH, FEI 3002806419, at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, from September 18 to 26, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 20, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nSignificant deficiencies were identified with aseptic processing controls in your (b)(4) and restricted access barrier system (RABS) processing lines used to aseptically manufacture sterile drug products for the U.S. market.\nCleaning and Disinfection\nYou used (b)(4) extensively to rinse critical, interior surfaces and aseptic processing equipment in your (b)(4) and RABS lines after production. This (b)(4) was fed from (b)(4) cleaning use points inside your (b)(4) and RABS through excessively long (up to approximately (b)(4)) deadlegs from your (b)(4) loop. Deadlegs in (b)(4) systems are known to cause stagnation of (b)(4) and excessive microbial growth.\nBetween June 2023 and September 2025, routine testing of (b)(4) cleaning use points in your ISO 5 (b)(4) and RABS resulted in at least 47 microbial recoveries, including 14 that exceeded your action limit. Your routine monitoring samples repeatedly recovered gram-negative, biofilm-forming, (b)(4) organisms including Sphingomonas, Methylobacterium, Bradyrhizobium, and Ralstonia species. Investigations for at least two incidents associated with microbial recoveries identified the design of your (b)(4) cleaning use point piping as the most likely root cause. However, your corrective action and preventive action (CAPA) plans have failed to comprehensively address the identified deficiencies in your (b)(4) system design.\nFurthermore, post-production environmental monitoring (EM) samples taken within your ISO 5 (b)(4) and RABS between June 2023 and September 2025 have resulted in repeated recoveries of gram-negative (b)(4) organisms including Sphingomonas, Methylobacterium, and Cupriavidus species.\nThis sampling identified a worrisome adverse trend in your RABS in late 2023 in which (b)(4) gaskets and (b)(4) were found to be contaminated with gram negative microbes. Significantly, too-numerous-to-count (TNTC) levels were present on RABS (b)(4) gaskets in multiple instances during this period. Your investigations acknowledged that equipment design (including (b)(4) gaskets) and maintenance, in combination with cleaning (e.g., residual (b)(4) from cleaning), caused the deviation.\nYou failed to sufficiently address the underlying cause of residual (b)(4) in a timely manner, instead relying on personnel to (b)(4) dry any observed moisture.\nIn your response, you commit to corrective actions including (b)(4) sanitization of (b)(4) cleaning use point piping and (b)(4) of the (b)(4) used in ISO 5 cleaning. Additionally, you explain your process of (b)(4)-drying your (b)(4) and RABS with (b)(4) drying of residual (b)(4) during visual inspection by operators. You also commit to implementing (b)(4) disinfection of the (b)(4) in your (b)(4) and RABS.\nYour response is inadequate because your corrective actions fail to address the fundamental, self-identified design flaw in your (b)(4) supply lines” that lead to each of your (b)(4) and RABS processing lines for cleaning. You also fail to holistically address residual (b)(4) from cleaning your (b)(4) and RABS units across your site. The residual (b)(4) issue poses a significant risk to barrier\u002F(b)(4) system control (e.g., interference with decontamination cycle efficacy) and can potentially lead to drug product contamination.\n(b)(4) Integrity Testing\nYou failed to adequately maintain equipment to assure aseptic conditions. Your (b)(4) integrity testing program for (b)(4) was found to be deficient. For example:\nYour (b)(4) integrity testing program for (b)(4) permitted (b)(4) to fail acceptance criteria during pressure decay testing (b)(4) times before requiring replacement. Your translated procedure states, “All (b)(4) that fail the leak test (pressure drop test) may be retested. If the (b)(4) fails more than (b)(4) times, it must be replaced.”\nWhen (b)(4) failed leak testing, retesting was often not performed the same day but at a later date. As a result, you manufactured drug products using (b)(4) that had failed leak testing without confirming their integrity. For example, (b)(4) on line (b)(4) failed to meet acceptance criteria on July 1, 2025, and did not pass testing until July 19, 2025. In the 18-day period between these tests, your production schedule indicated you manufactured at least (b)(4) batches of drug products.\nYou lacked raw (b)(4) testing data. During the inspection, you were unable to locate raw (b)(4) integrity testing data from (b)(4) for line (b)(4).\nInstead of reviewing raw (b)(4) testing data, your quality assurance unit relied on forms containing transcribed information.\nIn your response, you commit to enhancing your (b)(4) integrity testing program through procedural updates requiring additional quality oversight, defining actions following test failures including not permitting production to proceed “following an invalid or failed test,” and implementing quality review of visual and (b)(4) testing results.\nYou indicate that inappropriate acceptance criteria programmed into your (b)(4) integrity testing device caused many of the failures. You also assert, “[T]here has been no impact to any released batches or the overall control of sterility assurance at the site.”\nFurthermore, your response states that in your operators’ experience, pressure decay failures are generally not indicative of non-integral (b)(4), and they instead relied upon visual inspection.\nYour response calls into question the reliability of your (b)(4) integrity testing program. Visual inspections, on their own, are insufficient to monitor (b)(4) integrity. Visual (b)(4) examinations provide far lower detectability than, and cannot be substituted for, (b)(4) integrity testing devices. It is essential that your firm use (b)(4) integrity testing devices that are capable of reliably detecting sub-visible breaches in (b)(4) integrity.\nYou also failed to perform retrospective evaluation of potentially impacted products and processes. In response to the uninvestigated (b)(4) integrity failures, you concluded there was no quality impact to released batches or overall contamination risk at the site. However, you appear to have limited your review only to examples cited during the inspection.\nAdditionally, you failed to assess equipment management across your site to identify other potentially impacted critical equipment that may affect aseptic conditions. You should give continual attention to the integrity of critical equipment. This includes comprehensive maintenance procedures that establish adequate integrity testing and proactive replacement before breakdown.\nProtective Equipment Materials\nYou failed to implement other adequate equipment control systems to prevent contamination during aseptic processing. Our investigators observed particles shedding from (b)(4) material in aseptic areas. For example, loose, visible fibers were observed on and dislodging from (b)(4) covers during (b)(4) installation within critical aseptic filling areas. Fibers also were observed on tubing in two locations in line (b)(4). Subsequently, unused (b)(4) covers were inspected and observed to have loose fibers indicating the material itself was the source of contamination. You use the material is used to protect (b)(4) and the end of sterile tubing.\nFurthermore, this is an ongoing issue. Your customer reported your previous non-pharmaceutical grade (b)(4) material as a source of particulate contamination. In response, you introduced your current (b)(4) material across your (b)(4) and RABS processing lines without evaluating its particle generating characteristics.\nIn your response, you explain the (b)(4) seams on the (b)(4) are the apparent source of visible fibers and they appear to be statically charged. You also indicate you are working with your supplier to address this issue while taking interim controls including awareness training, visual checks of equipment at risk of fibers, removal of observed fibers with sterile lint-free wipes, and the exchange of equipment when fibers are observed attached to product contact surfaces.\nYour response is inadequate. You limited your retrospective batch review to only the two batches observed to be exposed to loose fibers during the inspection. Your response also fails to assess the particles generated by the (b)(4) material to determine their characteristics (e.g., size). Additionally, your response fails to support the adequacy of visual inspection as an interim control or to review quality indicators for particle related issues (e.g., complaints, deviations). Finally, your response did not address your failure to evaluate particle generation in the replacement material when you implemented a change control for (b)(4) in response to a particle generation complaint. This is a quality oversight failure.\nAseptic processing operations should be designed and executed to minimize exposure of sterile articles to potential contamination hazards in the manufacturing operation. Flaws in the design of cleanrooms and aseptic processing lines or improper execution of aseptic operations can enable entry of contaminants into the critical (ISO 5) processing area and lead to product contamination.\n(b)(4) technology represents a significant advance over traditional operational designs. However, all technologies have failure modes that require ongoing, vigilant monitoring and maintenance to ensure a state of control, including (b)(4). A strong quality system is essential to oversee design and construction of aseptic processing lines and supporting utilities, and to ensure ongoing proper operational control to safeguard against contamination hazards throughout the facility lifecycle.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide the following:\nA comprehensive assessment of your (b)(4) system design, control, and maintenance including, but not limited to:\no Identification of deadlegs and any other insanitary elements of your (b)(4) system.\no A comprehensive remediation plan and detailed CAPA timeline for improving design, control, and maintenance of your (b)(4) system. Include re-piping and modifications to eliminate deadlegs, removal of insanitary fittings, assurance of appropriately designed recirculating loops, and completion of all other needed remediations to ensure sanitary systems. Place special emphasis on identifying and eliminating any deadlegs that feed (b)(4), RABS, or other sterile production equipment.\no The validation report for the (b)(4) system after all identified design issues have been fully corrected and any maintenance repairs have been completed. Include the system validation protocol, the complete test results, and the final validation report. Include the summary of all improvements made to system design, as well as the program for ongoing control and maintenance.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of potential contamination from residual moisture after cleaning. For each production line, assess (b)(4) cleaning and (b)(4) drying cycles, identify specific equipment parts which remain within the (b)(4) and RABS after cleaning, and address the potential for (b)(4) to remain stagnant within equipment between production operations. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture products intended to be sterile.\nBased upon the cleaning effectiveness assessment, provide a CAPA detailing improvements to your cleaning and disinfection program including enhancements to cleaning effectiveness, improved ongoing verification of proper cleaning and disinfection execution for all products and equipment, and all other needed remediations.\nA comprehensive assessment of the design and control of your firm’s manufacturing operations with a detailed and thorough review of all microbiological hazards.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA comprehensive evaluation of your ongoing (b)(4) maintenance program.\no Address elements including, but not limited to, frequency of integrity tests (e.g., at least (b)(4)), (b)(4) testing procedure and methodology, and appropriate practices to reduce the occurrence of invalid tests.\no Conduct an analysis of the various failure scenarios that have occurred during your (b)(4) leak testing (e.g., device set-up problems, failure to meet initial pressure, employee interference). Also include further clarity on whether supervisors will be notified immediately, prior to initiation of a retest, of any instance of a (b)(4) integrity test failure.\no Include a product impact assessment.\no Provide associated CAPA.\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities. A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nA risk assessment addressing the use of shedding material within your critical ISO 5 production areas. Include a detailed summary of how you determined that your interim controls are adequate to prevent the contamination of products. Include details of your investigation such as evaluation of particle generation, particle size distribution, and the likelihood of detection by visual inspection. Discuss your investigation into potentially impacted lots of product including your evaluation of quality indicators such as complaints and deviations. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nYour (b)(4) cycles were inadequately validated to ensure that they were capable of consistently decontaminating all interior surfaces of your (b)(4) and multiple RABS lines in preparation for aseptic production.\nBiological Indicator Recoveries\nInadequacies in your (b)(4) process were demonstrated through a trend of routine recoveries of biological indicator (BI) growth at completion of validation cycles executed in your (b)(4) since 2022.\nNotably, your acceptance criteria were inappropriate in that they allowed routine recovery of multiple BI survivors. For example, positive BIs (upwards of 8 recoveries) were identified in nearly all validation cycles ((b)(4) of (b)(4)) between 2022 and 2025 on your lines (b)(4) lines. These positive BIs occurred at various locations within each line. However, based upon your inappropriate acceptance criteria, only two of the (b)(4) validation cycles were found to be unacceptable.\nFurthermore, you attributed recent validation failures in 2025 to “rogue” phenomenon in a BI lot, but this fails to recognize the multiple positive BIs that occurred with other BI lots in the same year. You also failed to acknowledge your long-term trend of routine BI positives in most of your (b)(4) validation studies.\nInadequate (b)(4) Validation\nYour (b)(4) validation did not demonstrate reliable decontamination cycle capability. For example:\n(b)(4) were not (b)(4) during the (b)(4) validation cycles such that (b)(4) were present in the (b)(4). Your validation instruction, PPVA VA 48074e\u002F03, appears to permit (b)(4) to rest on the bottom of (b)(4), creating an occluded surface which undermines the ability of (b)(4) to decontaminate this critical location.\nYou did not document or adequately specify each location of BI placement. You also lacked scientific evidence to support the triplicate BIs being representative of each location.\nYou allowed repetition of validation cycles without proper investigation in each instance of observed BI growth. Your (b)(4) validation cycle was repeated in your (b)(4) after initially failing to meet its acceptance criteria for positive BIs ((b)(4) out of (b)(4)).\nIn your response, you committed to assessing your (b)(4) for surface exposure and implementing remediations based on your findings where possible, increasing BIs in (b)(4) with (b)(4) for (b)(4) decontamination process validation, updating your procedures to address failed validation cycles, reducing the allowable BI growth, implementing investigational requirements for any BI growth, and optimizing the (b)(4) cycle in your (b)(4).\nYour response is inadequate. You failed to address multiple years of consistent recoveries of positive BIs across multiple locations within your (b)(4) during previous validation cycles. Recurrent failures are indicative of poor cycle robustness and require further investigation. Furthermore, your commitment to increase the number of BIs in (b)(4) does not address setup and configuration adaptations that can ensure consistent exposure of all interior surfaces to (b)(4).\nIncomplete exposure of interior surfaces to (b)(4) compromises decontamination effectiveness and places the (b)(4) and RABS environment at risk. Furthermore, as discussed above, the inconsistent removal of residual moisture prior to (b)(4) treatment of your (b)(4) and RABS could further compromise (b)(4) decontamination efficacy.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification and ongoing monitoring of variation to ensure a continuing state of control.\nA comprehensive, independent review of the adequacy of (b)(4) cycles. Place special attention on (b)(4) cycle stages including (b)(4). Provide a timeline for a detailed report on the findings of the independent review and associated CAPA activities (e.g., cycle parameter changes such as an increased decontamination phase duration; optimized airflow; improved surface exposure).\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your decontamination cycles that includes vigilant monitoring to ensure an ongoing state of control. Also, include your program for assuring ongoing state of control throughout your facility and equipment infrastructure.\nProcedures to ensure residual (b)(4) is appropriately removed from RABS and (b)(4) units before execution of (b)(4) cycles.\nRequest for a Meeting with FDA\nAfter you submit your response to this warning letter, we recommend you reach out to this office to arrange for a teleconference to discuss your corrective actions and preventive actions in detail. Please direct your request to Patricia Warren at patricia.warren@fda.hhs.gov and cc: CDER-OC-OMQ-Communications@fda.hhs.gov.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Simtra Deutschland GmbH located at Kantstr. 2, 33790 Halle\u002FWestphalia, Germany, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806419 and ATTN: Samantha Bradley.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nCC:\nRémi Helmig\nSite Director\nSimtra Deutschland GmbH\nKantstr. 2\n33790 Halle\u002FWestphalia\nGermany\nrhelmig@simtra.com\n_____________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Simtra BioPharma Solutions","simtra-biopharma-solutions-720436-03032026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsimtra-biopharma-solutions-720436-03032026","2026-10-26T08:09:57.988668+00:00","2026-03-10","720436","Franco Negron","2026-08-19T04:52:12.655+00:00","VIA UPS","320-26-49","2026-03-03",{"id":121,"raw":122,"subject":126,"body_html":127,"body_text":128,"firm_name":129,"letter_id":130,"created_at":42,"fei_number":19,"letter_url":131,"updated_at":132,"action_type":22,"case_status":23,"posted_date":133,"marcs_cms_no":134,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":135,"body_fetched_at":136,"delivery_method":117,"recipient_title":19,"reference_number":137,"action_taken_date":138,"medical_device_id":19,"response_letter_date":19},989,[123,124,125,36,126,13,13,13],"\u003Ctime datetime=\"2025-03-25T04:00:00Z\">03\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-05T05:00:00Z\">03\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-biopharma-labs-private-limited-698665-03052025\">Aspen Biopharma Labs Private Limited\u003C\u002Fa>","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-50\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. K. Sateesh Reddy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aspen Biopharma Labs Private Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Plot 10, Phase - II; Lalgadi Malakpet Village, Rangareddy\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hyderabad\u003C\u002Fspan> \u003Cspan>500078\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Telangana\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-50\u003C\u002Fp>\u003Cp>March 5, 2025\u003Cbr>\u003Cbr>Dear Mr. Reddy:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, at Aspen Biopharma Labs Private Limited, FEI 3012796281, at Plot 10, Phase – II; Lalgadi Malakpet Village, Rangareddy, Hyderabad, Telangana, 500078, India, from September 16 to September 21, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to design and construct buildings and facilities used in the manufacture of your API in a manner to minimize potential contamination, facilitate appropriate cleaning, maintenance, and operations.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You produce higher-risk APIs in an inadequate facility including one that lacks appropriate separation for high pharmacological activity or toxic materials including \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs. During the inspection, our investigator observed your facility was in a state of disrepair, with manufacturing areas open to the outdoor environment with inadequate protection of materials. Our investigator also observed that \u003Cstrong>(b)(4)\u003C\u002Fstrong> drugs were manufactured in a common area.\u003C\u002Fp>\u003Cp>For example, your firm stated that “all the operations are conducted under one roof in \u003Cstrong>(b)(4) \u003C\u002Fstrong>Block Annex without proper segregation” and that “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Block Annex manufacturing facility is in the process of demolish.” Of note, FDA collected batch indicating you produced drugs during this time period.\u003C\u002Fp>\u003Cp>In your response you indicate that your facility is undergoing renovations. Your response is inadequate because you did not provide sufficient details of how your facility design will prevent contamination of drug substances from the open environment, as well as cross-contamination of non-toxic drug substance from highly toxic components.\u003C\u002Fp>\u003Cp>It is expected that buildings used in the manufacture of APIs are designed and constructed to minimize potential contamination.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes and failure to adequately validate written procedures for the cleaning and maintenance of equipment.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to appropriately validate your processes and adequately qualify the equipment used to manufacture your drugs. Specifically, you have not completed process validation for commercial size lots of your APIs. For example, you rely on studies conducted on development lot sizes for \u003Cstrong>(b)(4)\u003C\u002Fstrong> API intermediates manufactured utilizing different equipment than that used for commercial production.\u003C\u002Fp>\u003Cp>In your response, you state that you compared commercial lots to the smaller development validation lots, found no significant variations, and will perform commercial size process validations. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant \u003Cstrong>(b)(4)\u003C\u002Fstrong> of a manufacturing process must be designed appropriately to assure the quality of raw material inputs, in-process materials, and finished APIs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process performance qualification (PPQ) studies incorporating the use of appropriately qualified equipment and validated test methods are necessary prior to commercial distribution. Thereafter, ongoing vigilant oversight of process performance and drug quality is necessary to ensure you maintain a stable manufacturing operation throughout the drug lifecycle. Failure to implement adequate analytical method validation practices can result in insufficient understanding of process variables or failure to detect a drift in capability, which increases the risk of drug quality defects. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You lacked cleaning validation studies that demonstrate your cleaning procedures are adequate. For example, you previously identified the need to implement a cleaning validation based on your internal deviation report, yet our investigator observed that you lack cleaning validation.\u003C\u002Fp>\u003Cp>In addition, our investigators observed manufacturing equipment labeled “Cleaned” that contained liquid with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> floating substance or residue on product-contact surfaces.\u003C\u002Fp>\u003Cp>In your response you indicate that you plan to perform cleaning validation for your drugs and perform hold time studies. Your response is inadequate because you did not provide supportive documentation or your interim plans for drug production while you complete corrective and preventive actions.\u003C\u002Fp>\u003Cp>Inadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety. Cleaning procedures should consider solubility, cleaning difficulty, and residue limits, while reproducible and effective for the removal or obliteration of previous lot identification and protection of clean equipment from contamination prior to use. Furthermore, the use of dedicated production areas should be considered for higher-risk material of an infectious nature or high pharmacological activity or toxicity (e.g., certain steroids or \u003Cstrong>(b)(4) \u003C\u002Fstrong>agents) where cleaning and inactivation alone are not sufficient controls.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the drug lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-lot and inter-lot variation to ensure a continuing state of control. This should include the process for selecting API lots to achieve the \u003Cstrong>(b)(4)\u003C\u002Fstrong> API blend.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed API. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>An assessment of each API process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o drugs with higher toxicities\u003Cbr>o drugs with higher drug potencies\u003Cbr>o drugs of lower solubility in their cleaning solvents\u003Cbr>o drugs with characteristics that make them difficult to clean\u003Cbr>o swabbing locations for areas that are most difficult to clean\u003Cbr>o maximum hold times before cleaning\u003Cbr>In addition, describe the steps that must be taken in your change management system before the introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of your updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drugs may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drugs and equipment; and all other needed remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to have originals or copies of records readily available and promptly retrievable during the retention period.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure adequate document control over paper and electronic records. For example, you provided a written statement on firm letterhead admitting to backdating a QC lab document and you signed a declaration confirming commercial drugs shipped to the US were not supported by appropriate original data.\u003C\u002Fp>\u003Cp>In your response, you acknowledge a lack of original data and that you will improve your document management system. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide a management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure to design a documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s stability program is inadequate. For example, your firm does not have adequate data to support the retest date for drugs shipped to the United States.\u003C\u002Fp>\u003Cp>In your response, you acknowledge the deficiencies of your stability program and propose corrective actions including addition of stability indicating analysis. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>Without an adequate stability program, you cannot ensure that your APIs meet established specifications and all pre-determined quality criteria throughout the APIs’ assigned shelf-life.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability-indicating methods.\u003Cbr>o Stability studies for each drug in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative lots of each drug is added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On January 14, 2025, FDA held a teleconference with you recommending you consider removing any lots of drugs currently in distribution from the U.S. market. On January 16, 2025, you agreed to voluntary recall of all drugs in current distribution in United States.\u003C\u002Fp>\u003Cp>We acknowledge that you initiated a voluntary nationwide recall on February 7, 2025, of all products distributed in the United States.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Status\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you deregistered your facility on January 6, 2025, however, it is unclear whether you intend to cease production of drugs for the U.S. market. In response to this letter, clarify whether you intend to cease manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether APIs are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed drugs offered for import into the U.S. from your firm on Import Alert 66-40 on January 15, 2025.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012796281 and ATTN: Reba Gates.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-50\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. K. Sateesh Reddy\n\nRecipient Title\n\nCEO\n\nAspen Biopharma Labs Private Limited\n\nPlot 10, Phase - II; Lalgadi Malakpet Village, Rangareddy\n\nHyderabad 500078\n\nTelangana\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-50\nMarch 5, 2025\n\nDear Mr. Reddy:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, at Aspen Biopharma Labs Private Limited, FEI 3012796281, at Plot 10, Phase – II; Lalgadi Malakpet Village, Rangareddy, Hyderabad, Telangana, 500078, India, from September 16 to September 21, 2024.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence\nDuring our inspection, our investigators observed deviations including, but not limited to, the following.\n1. Failure to design and construct buildings and facilities used in the manufacture of your API in a manner to minimize potential contamination, facilitate appropriate cleaning, maintenance, and operations.\nYou produce higher-risk APIs in an inadequate facility including one that lacks appropriate separation for high pharmacological activity or toxic materials including (b)(4) drugs. During the inspection, our investigator observed your facility was in a state of disrepair, with manufacturing areas open to the outdoor environment with inadequate protection of materials. Our investigator also observed that (b)(4) drugs were manufactured in a common area.\nFor example, your firm stated that “all the operations are conducted under one roof in (b)(4) Block Annex without proper segregation” and that “(b)(4) Block Annex manufacturing facility is in the process of demolish.” Of note, FDA collected batch indicating you produced drugs during this time period.\nIn your response you indicate that your facility is undergoing renovations. Your response is inadequate because you did not provide sufficient details of how your facility design will prevent contamination of drug substances from the open environment, as well as cross-contamination of non-toxic drug substance from highly toxic components.\nIt is expected that buildings used in the manufacture of APIs are designed and constructed to minimize potential contamination.\nIn response to this letter provide:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n2. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes and failure to adequately validate written procedures for the cleaning and maintenance of equipment.\nProcess Validation\nYou failed to appropriately validate your processes and adequately qualify the equipment used to manufacture your drugs. Specifically, you have not completed process validation for commercial size lots of your APIs. For example, you rely on studies conducted on development lot sizes for (b)(4) API intermediates manufactured utilizing different equipment than that used for commercial production.\nIn your response, you state that you compared commercial lots to the smaller development validation lots, found no significant variations, and will perform commercial size process validations. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant (b)(4) of a manufacturing process must be designed appropriately to assure the quality of raw material inputs, in-process materials, and finished APIs. Process qualification studies determine whether an initial state of control has been established.\nSuccessful process performance qualification (PPQ) studies incorporating the use of appropriately qualified equipment and validated test methods are necessary prior to commercial distribution. Thereafter, ongoing vigilant oversight of process performance and drug quality is necessary to ensure you maintain a stable manufacturing operation throughout the drug lifecycle. Failure to implement adequate analytical method validation practices can result in insufficient understanding of process variables or failure to detect a drift in capability, which increases the risk of drug quality defects. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nCleaning Validation\nYou lacked cleaning validation studies that demonstrate your cleaning procedures are adequate. For example, you previously identified the need to implement a cleaning validation based on your internal deviation report, yet our investigator observed that you lack cleaning validation.\nIn addition, our investigators observed manufacturing equipment labeled “Cleaned” that contained liquid with a (b)(4) floating substance or residue on product-contact surfaces.\nIn your response you indicate that you plan to perform cleaning validation for your drugs and perform hold time studies. Your response is inadequate because you did not provide supportive documentation or your interim plans for drug production while you complete corrective and preventive actions.\nInadequately cleaned and maintained manufacturing equipment can lead to potential cross-contamination that could compromise your API’s quality and safety. Cleaning procedures should consider solubility, cleaning difficulty, and residue limits, while reproducible and effective for the removal or obliteration of previous lot identification and protection of clean equipment from contamination prior to use. Furthermore, the use of dedicated production areas should be considered for higher-risk material of an infectious nature or high pharmacological activity or toxicity (e.g., certain steroids or (b)(4) agents) where cleaning and inactivation alone are not sufficient controls.\nIn response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the drug lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-lot and inter-lot variation to ensure a continuing state of control. This should include the process for selecting API lots to achieve the (b)(4) API blend.\nA timeline for performing appropriate PPQ for each of your marketed API. Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\nAn assessment of each API process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no drugs with higher toxicities\no drugs with higher drug potencies\no drugs of lower solubility in their cleaning solvents\no drugs with characteristics that make them difficult to clean\no swabbing locations for areas that are most difficult to clean\no maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before the introduction of new manufacturing equipment or a new product.\nA summary of your updated standard operating procedures that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated drugs may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all drugs and equipment; and all other needed remediations.\n3. Failure to have originals or copies of records readily available and promptly retrievable during the retention period.\nYou failed to ensure adequate document control over paper and electronic records. For example, you provided a written statement on firm letterhead admitting to backdating a QC lab document and you signed a declaration confirming commercial drugs shipped to the US were not supported by appropriate original data.\nIn your response, you acknowledge a lack of original data and that you will improve your document management system. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide a management strategy for your firm that includes the details of your global CAPA plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n4. Failure to design a documented, on-going stability testing program to monitor the stability characteristics of API and to use the results to confirm appropriate storage conditions and retest or expiry dates.\nYour firm’s stability program is inadequate. For example, your firm does not have adequate data to support the retest date for drugs shipped to the United States.\nIn your response, you acknowledge the deficiencies of your stability program and propose corrective actions including addition of stability indicating analysis. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\nWithout an adequate stability program, you cannot ensure that your APIs meet established specifications and all pre-determined quality criteria throughout the APIs’ assigned shelf-life.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability-indicating methods.\no Stability studies for each drug in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative lots of each drug is added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\nDrug Recall\nOn January 14, 2025, FDA held a teleconference with you recommending you consider removing any lots of drugs currently in distribution from the U.S. market. On January 16, 2025, you agreed to voluntary recall of all drugs in current distribution in United States.\nWe acknowledge that you initiated a voluntary nationwide recall on February 7, 2025, of all products distributed in the United States.\nDrug Production Status\nWe acknowledge that you deregistered your facility on January 6, 2025, however, it is unclear whether you intend to cease production of drugs for the U.S. market. In response to this letter, clarify whether you intend to cease manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nAdditional API CGMP Guidance\nFDA considers the expectations outlined in ICH Q7 when determining whether APIs are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed drugs offered for import into the U.S. from your firm on Import Alert 66-40 on January 15, 2025.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3012796281 and ATTN: Reba Gates.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Aspen Biopharma Labs Private Limited","aspen-biopharma-labs-private-limited-698665-03052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faspen-biopharma-labs-private-limited-698665-03052025","2026-10-26T08:07:58.483518+00:00","2025-03-25","698665","Mr. K. Sateesh Reddy","2026-08-19T16:54:47.671+00:00","320-25-50","2025-03-05",{"id":140,"raw":141,"subject":105,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":42,"fei_number":19,"letter_url":149,"updated_at":150,"action_type":22,"case_status":23,"posted_date":151,"marcs_cms_no":152,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":153,"body_fetched_at":154,"delivery_method":155,"recipient_title":19,"reference_number":156,"action_taken_date":157,"medical_device_id":19,"response_letter_date":19},577,[142,143,144,36,105,13,13,13],"\u003Ctime datetime=\"2025-09-23T04:00:00Z\">09\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-11T04:00:00Z\">09\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchengdu-brilliant-biopharmaceutical-co-ltd-711330-09112025\">Chengdu Brilliant Biopharmaceutical Co., Ltd. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail Return Confirmation Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-109\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Zeng Dong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Chengdu Brilliant Biopharmaceutical Co., Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>#33, Tengfei 12th Rd, Southwest Airport Economic Dev Zn\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shuangliu Xian\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chengdu Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sichuan Sheng\u003C\u002Fspan>, \u003Cspan>610207\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-109\u003C\u002Fp>\u003Cp>September 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Zeng Dong:\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our March 12, 2025, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Chengdu Brilliant Biopharmaceutical Co., Ltd., FEI 3015530591, at #33, Tengfei 12th Road, Southwest Airport Economic Dev Zn, Shuangliu District Chengdu, Sichuan.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant deviations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm has not conducted process validation for the Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) API Semaglutide manufactured at your site.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>Without adequate process validation, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s) and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to test the identity of each batch of incoming production material.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you failed to conduct an identity test on the raw materials used for manufacturing of your API during \u003Cstrong>(b)(4)\u003C\u002Fstrong>, e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without adequate testing, there is no scientific evidence to assure that your raw materials conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, please provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on July 9, 2025.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Chengdu Brilliant Biopharmaceutical Co., Ltd., FEI 3015530591, at #33, Tengfei 12th Road, Southwest Airport Economic Dev Zn, Shuangliu District Chengdu into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015530591 and ATTN: Chhaya Shetty.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail Return Confirmation Requested\n\nReference #:\n\n320-25-109\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Zeng Dong\n\nRecipient Title\n\nGeneral Manager\n\nChengdu Brilliant Biopharmaceutical Co., Ltd.\n\n#33, Tengfei 12th Rd, Southwest Airport Economic Dev Zn\n\nShuangliu Xian\n\nChengdu Shi\n\nSichuan Sheng, 610207\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-109\nSeptember 11, 2025\nDear Mr. Zeng Dong:\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our March 12, 2025, request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Chengdu Brilliant Biopharmaceutical Co., Ltd., FEI 3015530591, at #33, Tengfei 12th Road, Southwest Airport Economic Dev Zn, Shuangliu District Chengdu, Sichuan.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant deviations were observed including, but not limited to, the following:\n1. Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.\nBased on the records and information you provided, your firm has not conducted process validation for the Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) API Semaglutide manufactured at your site.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\nWithout adequate process validation, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide the following:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ for each of your marketed drug products.\nProcess performance protocol(s) and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n2. Failure to test the identity of each batch of incoming production material.\nBased on the records and information you provided, you failed to conduct an identity test on the raw materials used for manufacturing of your API during (b)(4), e.g., (b)(4).\nWithout adequate testing, there is no scientific evidence to assure that your raw materials conform to appropriate specifications before release.\nIn response to this letter, please provide the following:\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on July 9, 2025.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Chengdu Brilliant Biopharmaceutical Co., Ltd., FEI 3015530591, at #33, Tengfei 12th Road, Southwest Airport Economic Dev Zn, Shuangliu District Chengdu into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3015530591 and ATTN: Chhaya Shetty.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Chengdu Brilliant Biopharmaceutical Co., Ltd.","chengdu-brilliant-biopharmaceutical-co-ltd-711330-09112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fchengdu-brilliant-biopharmaceutical-co-ltd-711330-09112025","2026-10-26T08:08:14.253645+00:00","2025-09-23","711330","Mr. Zeng Dong","2026-08-19T16:17:44.354+00:00","Via Electronic Mail Return Confirmation Requested","320-25-109","2025-09-11",{"id":159,"raw":160,"subject":105,"body_html":166,"body_text":167,"firm_name":168,"letter_id":169,"created_at":170,"fei_number":19,"letter_url":171,"updated_at":172,"action_type":22,"case_status":173,"posted_date":174,"marcs_cms_no":175,"product_type":47,"closeout_date":176,"issuing_office":164,"recipient_name":177,"body_fetched_at":178,"delivery_method":179,"recipient_title":19,"reference_number":19,"action_taken_date":180,"medical_device_id":19,"response_letter_date":19},2510,[161,162,163,164,105,13,165,13],"\u003Ctime datetime=\"2022-08-16T13:20:00Z\">08\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-10T04:00:00Z\">08\u002F10\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcangene-biopharma-llc-dba-emergent-biosolutions-630316-08102022\">Cangene BioPharma, LLC dba Emergent BioSolutions\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcangene-biopharma-llc-630316-10042023\">\u003Ctime datetime=\"2023-10-04T04:00:00Z\">10\u002F04\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Robert Kramer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer (CEO)\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cangene BioPharma, LLC dba Emergent BioSolutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>400 Professional Drive Suite 400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaithersburg\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20879\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>CMS # 630316\u003C\u002Fp>\n\n\u003Cp>August 10, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Kramer:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cangene BioPharma, LLC dba Emergent BioSolutions, FEI 1000512361, at 1111 South Paca Street, Baltimore, MD 21230, from February 7 to 11, 2022, and from February 14 to 18, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 10, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, and you failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) and (b)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour system for ensuring suitable design and adequate control of equipment was deficient. Your firm failed to use suitable equipment for aseptic manufacturing, which led to particulate contamination of your sterile drug products.\u003C\u002Fp>\n\n\u003Cp>Multiple customer complaint investigations related to the presence of foreign particulates (i.e., metal particulates) in your drug products determined that the root cause was associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> tray units, both equipment that are present in your manufacturing environment and used in your aseptic processing operations. One of the investigations documented that seven vials were found to have metal particulates and an additional vial was found to have silicone particulates. The investigation also deemed the metal and other particulates to be “intrinsic” to the manufacturing process and stated that no further action was required. Your investigation added that the metal particulates likely entered the vials through manipulation of your tray units.\u003C\u002Fp>\n\n\u003Cp>You examined approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> tray units and found that most \u003Cstrong>(b)(4)\u003C\u002Fstrong> needed to be further evaluated due to apparent damage. Further evaluation of your tray units confirmed they were inadequate for use in sterile drug production and should have been removed as part of preventive maintenance.\u003C\u002Fp>\n\n\u003Cp>Your procedure for maintenance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tray units was inadequate. Your procedure, “SOP 9087, Inspection, Cleaning, and Storage Procedures for Trays and \u003Cstrong>(b)(4)\u003C\u002Fstrong>” indicated that tray units should be visually inspected prior to use in the manufacturing process, however, it lacked specificity regarding how you document your activities for the inspection, identification, segregation, evaluation, and repair and\u002For retirement of defective tray units. Our investigator also noted that you lacked documentation and adequate reconcilability for the visual inspection of tray units.\u003C\u002Fp>\n\n\u003Cp>In your response, you state you will initiate improved inspection of all tray units, and any confirmed unacceptable trays will be submitted for repair and\u002For replacement. You also commit to revise your SOP 9087, “Inspection, Cleaning, and Storage Procedures for Trays and \u003Cstrong>(b)(4)\u003C\u002Fstrong>,” to include examples of conditions that require maintenance assessment for repair or replacement (e.g., excessive scratching, old age, and worn appearance).\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide substantive evidence that your tray units are suitable for their intended purpose. Your response also lacks a systemic review of the preventive maintenance program used by your facility, including but not limited to replacement frequencies. Furthermore, you did not provide documentation of the actions taken on the defective tray units you evaluated. Also, you did not provide sufficient details regarding how your firm will ensure tray units are effectively identified and tracked (i.e., with unique identification number) to ensure suitability prior to use in production.\u003C\u002Fp>\n\n\u003Cp>Your response also fails to address how you will ensure adequate investigation of intrinsic and extrinsic visible particulate contamination issues. You do not commit to accurately define and categorize intrinsic and extrinsic particulates in your operation, and to properly evaluate visible particulate contamination in your parenteral products. It is important that intrinsic visible particulate contamination is appropriately evaluated and investigated. In addition, extrinsic or foreign particulate contamination should occur very infrequently and be thoroughly investigated.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>A CAPA plan, based on the retrospective assessment, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review and remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> units used in your manufacturing process.\u003C\u002Fli>\n\t\u003Cli>Your revised procedure(s) which include the identification of all \u003Cstrong>(b)(4)\u003C\u002Fstrong> tray units, and the process of tracking and tracing for maintenance and determining suitability for use.\u003C\u002Fli>\n\t\u003Cli>An independent review of your classification and investigation of particulate contamination in your products. The review should comprehensively assess your program, including but not limited to ensuring appropriate classifications of particulates (e.g., inherent, intrinsic, extrinsic), and appropriate investigations and CAPA.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to, evaluating:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o sufficiency of provisions used for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o whether an effective and complete final review of each batch and its related information is conducted before the QU disposition decision\u003Cbr>\n&nbsp; o implementation of oversight and approval of investigations, as well as discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>Also, describe how top management at your company supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your aseptic filling line operations required extensive \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions during the manufacturing process. Our investigators observed numerous instances of poor aseptic technique by your operators while performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions during production runs. Examples of these poor aseptic techniques include, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An operator was leaning into the aseptic filling cabinet which caused blockage of the unidirectional airflow over open glass vials. Notably, there was no subsequent clearance of the vials on the line exposed to potential contamination hazard.\u003C\u002Fli>\n\t\u003Cli>An operator left the filling cabinet door open for an excessive period.\u003C\u002Fli>\n\t\u003Cli>Poor practices by operators when manipulating vial tray containers and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for charging these trays.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In addition, sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> used for \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions inside the filling line cabinet were stored outside the cabinet, adjacent to the swing door. The inadequate storage location of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> increases the potential for their contamination.\u003C\u002Fp>\n\n\u003Cp>Your SOP 9002, “Personnel Conduct in the Sterile Core”, Section 6.3 (Material Handling), under subsection 6.3.2 states that personnel should “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”. Also, sub-section 6.3.8 mentions that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>...”. Your procedure is deficient in that it did not strictly instruct personnel to not disrupt the path of unidirectional air flow during sterile manufacturing process.\u003C\u002Fp>\n\n\u003Cp>To safeguard sterility of the drug product in aseptic processing operations, you must establish robust operational design and procedures, and personnel must employ strict discipline. The poor aseptic techniques observed during the inspection could cause potential breaches in sterility assurance.\u003C\u002Fp>\n\n\u003Cp>You state you have made improvements to your program for monitoring aseptic processing personnel behavior and classroom training on aseptic behaviors.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not indicate whether you have conducted a risk assessment that encompasses all batches within expiry and reviewed available videos associated with the batches to identify any poor aseptic practices and associated risks to your marketed drug products. Additionally, you do not provide the procedure for the aseptic processing behavior monitoring program that describes how you will document and evaluate observation(s) to determine if identified aseptic deviations may have impacted drug sterility.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of QU oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fli>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o all human interactions within the ISO 5 area\u003Cbr>\n&nbsp; o equipment placement and ergonomics\u003Cbr>\n&nbsp; o air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; o facility layout\u003Cbr>\n&nbsp; o personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Similar deviations were cited in a previous inspection, conducted from April 12 to 16, 2021, and discussed during the regulatory meeting held on October 6, 2021. You responded by proposing specific remediations to address these observations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective operations oversight to ensure reliable operations, we found that your QU was not fully exercising its authority or responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and products manufactured by your firm conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 630316 and include FEI: 1000512361\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact Jose Hernandez-Guzman, Compliance Officer at jose.hernandez-guzman@fda.hhs.gov or 631-787-3002 x1017.\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Nerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I\u003Cbr>\nNew Jersey District\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Robert Kramer\n\nRecipient Title\n\nChief Executive Officer (CEO)\n\nCangene BioPharma, LLC dba Emergent BioSolutions\n\n400 Professional Drive Suite 400\n\nGaithersburg, MD 20879\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter CMS # 630316\n\nAugust 10, 2022\n\nDear Mr. Kramer:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cangene BioPharma, LLC dba Emergent BioSolutions, FEI 1000512361, at 1111 South Paca Street, Baltimore, MD 21230, from February 7 to 11, 2022, and from February 14 to 18, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 10, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements, and you failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(a) and (b)).\n\nYour system for ensuring suitable design and adequate control of equipment was deficient. Your firm failed to use suitable equipment for aseptic manufacturing, which led to particulate contamination of your sterile drug products.\n\nMultiple customer complaint investigations related to the presence of foreign particulates (i.e., metal particulates) in your drug products determined that the root cause was associated with the (b)(4) and (b)(4) tray units, both equipment that are present in your manufacturing environment and used in your aseptic processing operations. One of the investigations documented that seven vials were found to have metal particulates and an additional vial was found to have silicone particulates. The investigation also deemed the metal and other particulates to be “intrinsic” to the manufacturing process and stated that no further action was required. Your investigation added that the metal particulates likely entered the vials through manipulation of your tray units.\n\nYou examined approximately (b)(4) tray units and found that most (b)(4) needed to be further evaluated due to apparent damage. Further evaluation of your tray units confirmed they were inadequate for use in sterile drug production and should have been removed as part of preventive maintenance.\n\nYour procedure for maintenance of (b)(4) tray units was inadequate. Your procedure, “SOP 9087, Inspection, Cleaning, and Storage Procedures for Trays and (b)(4)” indicated that tray units should be visually inspected prior to use in the manufacturing process, however, it lacked specificity regarding how you document your activities for the inspection, identification, segregation, evaluation, and repair and\u002For retirement of defective tray units. Our investigator also noted that you lacked documentation and adequate reconcilability for the visual inspection of tray units.\n\nIn your response, you state you will initiate improved inspection of all tray units, and any confirmed unacceptable trays will be submitted for repair and\u002For replacement. You also commit to revise your SOP 9087, “Inspection, Cleaning, and Storage Procedures for Trays and (b)(4),” to include examples of conditions that require maintenance assessment for repair or replacement (e.g., excessive scratching, old age, and worn appearance).\n\nYour response is inadequate. You did not provide substantive evidence that your tray units are suitable for their intended purpose. Your response also lacks a systemic review of the preventive maintenance program used by your facility, including but not limited to replacement frequencies. Furthermore, you did not provide documentation of the actions taken on the defective tray units you evaluated. Also, you did not provide sufficient details regarding how your firm will ensure tray units are effectively identified and tracked (i.e., with unique identification number) to ensure suitability prior to use in production.\n\nYour response also fails to address how you will ensure adequate investigation of intrinsic and extrinsic visible particulate contamination issues. You do not commit to accurately define and categorize intrinsic and extrinsic particulates in your operation, and to properly evaluate visible particulate contamination in your parenteral products. It is important that intrinsic visible particulate contamination is appropriately evaluated and investigated. In addition, extrinsic or foreign particulate contamination should occur very infrequently and be thoroughly investigated.\n\nIn response to this letter, provide:\n\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nA CAPA plan, based on the retrospective assessment, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\n\nA comprehensive, independent review and remediation plan for the design, control, and maintenance of the (b)(4) units used in your manufacturing process.\n\nYour revised procedure(s) which include the identification of all (b)(4) tray units, and the process of tracking and tracing for maintenance and determining suitability for use.\n\nAn independent review of your classification and investigation of particulate contamination in your products. The review should comprehensively assess your program, including but not limited to ensuring appropriate classifications of particulates (e.g., inherent, intrinsic, extrinsic), and appropriate investigations and CAPA.\n\nA comprehensive assessment and remediation plan to ensure your quality unit (QU) is given the authority and resources to effectively function. The assessment should also include, but not be limited to, evaluating:\n\no whether procedures used by your firm are robust and appropriate\n\no sufficiency of provisions used for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no whether an effective and complete final review of each batch and its related information is conducted before the QU disposition decision\n\no implementation of oversight and approval of investigations, as well as discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nAlso, describe how top management at your company supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour aseptic filling line operations required extensive (b)(4) interventions during the manufacturing process. Our investigators observed numerous instances of poor aseptic technique by your operators while performing (b)(4) interventions during production runs. Examples of these poor aseptic techniques include, but are not limited to:\n\nAn operator was leaning into the aseptic filling cabinet which caused blockage of the unidirectional airflow over open glass vials. Notably, there was no subsequent clearance of the vials on the line exposed to potential contamination hazard.\n\nAn operator left the filling cabinet door open for an excessive period.\n\nPoor practices by operators when manipulating vial tray containers and the (b)(4) used for charging these trays.\n\nIn addition, sterile (b)(4) used for (b)(4) interventions inside the filling line cabinet were stored outside the cabinet, adjacent to the swing door. The inadequate storage location of the (b)(4) increases the potential for their contamination.\n\nYour SOP 9002, “Personnel Conduct in the Sterile Core”, Section 6.3 (Material Handling), under subsection 6.3.2 states that personnel should “(b)(4)”. Also, sub-section 6.3.8 mentions that “(b)(4)...”. Your procedure is deficient in that it did not strictly instruct personnel to not disrupt the path of unidirectional air flow during sterile manufacturing process.\n\nTo safeguard sterility of the drug product in aseptic processing operations, you must establish robust operational design and procedures, and personnel must employ strict discipline. The poor aseptic techniques observed during the inspection could cause potential breaches in sterility assurance.\n\nYou state you have made improvements to your program for monitoring aseptic processing personnel behavior and classroom training on aseptic behaviors.\n\nYour response is inadequate. You do not indicate whether you have conducted a risk assessment that encompasses all batches within expiry and reviewed available videos associated with the batches to identify any poor aseptic practices and associated risks to your marketed drug products. Additionally, you do not provide the procedure for the aseptic processing behavior monitoring program that describes how you will document and evaluate observation(s) to determine if identified aseptic deviations may have impacted drug sterility.\n\nIn response to this letter, provide:\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of QU oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no all human interactions within the ISO 5 area\n\no equipment placement and ergonomics\n\no air quality in the ISO 5 area and surrounding room\n\no facility layout\n\no personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the independent contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nRepeat Violations at Facility\n\nSimilar deviations were cited in a previous inspection, conducted from April 12 to 16, 2021, and discussed during the regulatory meeting held on October 6, 2021. You responded by proposing specific remediations to address these observations. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective operations oversight to ensure reliable operations, we found that your QU was not fully exercising its authority or responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and products manufactured by your firm conform to FDA requirements.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM1_RESPONSES@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 630316 and include FEI: 1000512361\n\nIf you have questions regarding the content of this letter, please contact Jose Hernandez-Guzman, Compliance Officer at jose.hernandez-guzman@fda.hhs.gov or 631-787-3002 x1017.\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nOffice of Pharmaceutical Quality Operations Division I\n\nNew Jersey District","Cangene BioPharma, LLC dba Emergent BioSolutions","cangene-biopharma-llc-dba-emergent-biosolutions-630316-08102022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcangene-biopharma-llc-dba-emergent-biosolutions-630316-08102022","2026-10-26T08:08:10.773556+00:00","Closed Out","2022-08-16","630316","2023-10-04","Mr. Robert Kramer","2026-08-20T01:39:39.724+00:00","Via Email","2022-08-10",9,{"510k":183,"classification":184,"enforcement":185,"event":186,"event_backfill":187,"pma":188,"warning_letter":189},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]